Curriculum Vitae JANET KAZUKO YAMAMOTO, Ph.D

Curriculum Vitae JANET KAZUKO YAMAMOTO, Ph.D.

PRESENT POSITION: RESIDENCE:

Professor 4309 SW 77th Street Department of Infectious Diseases & Pathology (ID&P) Gainesville, Florida 32608 College of Veterinary Medicine Phone: (352) 371-9219 University of Florida, PO Box 110880 Fax: (352) 337-0444 Gainesville, FL 32611-0880 Phone: (352) 294-4145 Fax: (352) 392-7128 E-mail: [email protected]

EMPLOYMENT HISTORY:

1979-1981 James W. McLaughlin Predoctoral Fellow in Infection and Immunity, Department of Microbiology, The University of Texas Medical Branch, Galveston, (Supervisor, Dr. Howard M. Johnson). Characterized the xenogeneic responses observed during the interaction of human peripheral blood lymphocytes and mouse spleen cells. Identified human natural killer cell activity towards mouse immunocytes, nonspecific soluble helper activity of human T cells towards mouse antibody response, and suppressor cell activity of mitogen and alloantigen-stimulated human T cells towards mouse antibody response.

1981-1982 NIH PHS Postdoctoral Fellow in the laboratory of Drs. Richard W. Dutton and Susan L. Swain, Department of Biology, University of California, San Diego. Evaluated the role of lymphokines (interleukin-2 and interferon-γ) in the developing primary and secondary antibody responses in mice.

1982-1983 Research Associate Scientist in the laboratory of Drs. Robert A. Good and N.K. Day, Oklahoma Medical Research Foundation, Oklahoma City. Analyzed the immunological status of feline leukemia virus (FeLV)-positive cats that were undergoing ex vivo immunoabsorption therapy with protein A column.

1983-1985 Postgraduate Researcher IV in the Department of Medicine, School of Veterinary Medicine, University of California, Davis. Produced and purified feline interferons (α, ß, and γ) and characterized their effect against FeLV. Received New Investigator Research Award (1984-1987) from NCI, NIH to conduct research on the role of lymphokines in FeLV-induced immunosuppression and leukemia. Recruited concurrently in the fall of 1984 by Dr. Murray B. Gardner to establish the UCD AIDS Laboratory and to supervise the large-scale production and purification of HIV isolates for the Department of Pathology, School of Medicine, UCD.

1985 -1991 Assistant Research Immunologist I, II, III, IV, in the Department of Medicine, School of Veterinary Medicine, University of California, Davis. Served as a member of Center Janet K. Yamamoto   for AIDS Research (CFAR) at UCD and directed a research program on characterization of FIV immunopathogenesis, development of effective FIV vaccines, and identifying innovative immunotherapeutic approaches against animal and human AIDS.

1991-1993 Adjunct Associate Professor I (starting July 1, 1992) / Associate Research Immunologist I (1991 to June 30, 1992) in the Department of Medicine, School of Veterinary Medicine, University of California, Davis. Served as a member of CFAR at UCD and directed a research program identifying immune mechanism(s) of FIV vaccine protection and determining the immunopathological effects of B-cell hyperactivities in FIV infected cats.

1993-present. Associate Professor (tenured 1997) / Professor (promoted 2001) in the Department of Infectious Diseases & Pathology*, College of Veterinary Medicine, University of Florida, Gainesville, Florida. Responsible for teaching and coordinating veterinary immunology course (1993-2005); research director of the FIV vaccine and immunotherapy program; founder and executive member of Comparative Clinical Immunology Program. Affiliate faculty of Microbiology and Cell Sciences, Institute of Food and Agricultural Sciences (IFAS), University of Florida (1993-pres.).

* Please note that the Department of Infectious Diseases & Pathology was initially called the Department of Pathobiology upon fusion of two College of Veterinary Medicine (CVM) departments, the Department of Comparative & Experimental Pathology and the Department of Infectious Diseases, and to its current name in December of 2005.

EDUCATION: 1976 B.A. in Biological Sciences, University of California, Davis, California. 1981 Ph.D. in Microbiology (Immunology major, Virology minor), The University of Texas Medical Branch, Galveston, Texas.

MEMBERSHIP IN SCIENTIFIC ORGANIZATIONS: American Association of Immunologists American Society for Microbiology American Association for the Advancement of Science New York Academy of Sciences International AIDS Society Clinical Immunology Society

Janet K. Yamamoto   HONORS: 1979-1981 James W. McLaughlin Predoctoral Fellow in Infection and Immunity. 1984-1987 New Investigator Research Award, NCI, NIH. 1988 Rhone Merieux Workshop on Animal AIDS Models (Invited Speaker), Lyon, France. 1988 World Health Organization Conference on Animal Models of AIDS (Invited Speaker), Geneva, Switzerland. 1991 International Feline Immunology and Immunodeficiency Workshop (Invited Speaker), Glasgow, UK. 1992 Septieme Colloque Des Cent Gardes on Retroviruses of Human AIDS and Related Animal Diseases (Invited Speaker), Pasteur Institute, Marnes-la-Coquette, France. 1993 Annual Meeting by NIH, NCI, Laboratory of Tumor Cell Biology (Invited Speaker). 1995 XVIII Symposium of the International Association for Comparative Research on Leukemia and Related Diseases in Kyoto, Japan (Invited Speaker). 1996 Pfizer Animal Health Award for Research Excellence at the University of Florida, College of Veterinary Medicine (cited in JAVMA, 209:710). 1997 Plenary lecturer for Vaccine Section, 2nd Intl. Feline Immunol. Workshop, Davis, CA. 2002 The University of Florida Research Foundation Professors Award. 2002 Honorary Member of Upsilon Chapter of The Society of Phi Zeta (Honor Society of Veterinary Medicine). 2002 America’s Registry of Outstanding Professionals. 2003 Who’s Who in Veterinary Medicine Higher Education. 2003 Who’s Who in Science and Engineering. 2005 Pfizer Animal Health Award for Research Excellence at the University of Florida, College of Veterinary Medicine (received this award twice). 2006 Who’s Who in America. 2007 Faculty Achievement Recognition at the University of Florida. 2014 National Academy of Inventors (NIA) Fellow. 2015 Congressional Record – Extension of Remarks on 02/20/2015 on 2014 NAI 2015 Florida Inventors Hall of Fame.

PROFESSIONAL ACCOMPLISHMENTS:

BSL-3 Laboratories • Assisted in establishing the first UCD AIDS BSL-3 laboratory in 1984 as a joint venture for the Schools of Medicine and Veterinary Medicine; in charge of large-scale production of three HIV-1 strains for development of immunodiagnostics. This laboratory eventually became UCD AIDS Diagnostic Laboratory in 1986 which served as a major HIV-1 BSL-3 facility for the Center for AIDS Research (CFAR) grant awarded to UCD.

• Served as the member of the NIH-funded CFAR at UCD (1985-1993) and pursued independent research program in retrovirology and immunology in the second AIDS BSL-3 laboratory.

Janet K. Yamamoto   • Established and successfully operated numerous BSL-2+ and BSL-3 laboratories. Served as a consultant to the development of the second FDA-approved HIV immunoblot by Bio-Rad Laboratories in 1988. Directed and managed collaborative research projects on evaluating relative efficacies of therapeutic drugs and vaccine approaches against a number of feline and human viral infections. The work on HIV included evaluating in vitro drug efficacy and toxicity.

Discoveries and Developments • Co-discovered, characterized, and co-patented the feline interferon-/ (U.S. Patent No. 4,861,720) (1986). Performed phase-I trials as a joint venture with a Japanese firm under UCD contract (1988-1990). Released feline interferon license to a Japanese biochemical corporation for therapeutic use in viral diseases of cats and dogs. Currently receiving royalty income.

• Co-discovered, characterized, and co-patented the FIV (U.S. Patent Nos. 5,037,753; 5,118,602) (1986-1987). This virus which closely mimics human immunodeficiency virus (HIV) is useful in studying the pathogenesis of lentiviruses, in testing combinations of antiviral and immunomodulating drugs, and in evaluating vaccine approaches for AIDS. Developed, characterized, and patented IL-2-independent FIV producer cell lines to be used for developing FIV vaccine and diagnostics (U.S. Patent Application No. 5,275,813; 5,275,813; 5,510,106) (1990).

• Developed, characterized, and patented multi-subtype FIV vaccines (U.S. Patent No. 6,447,993B1; European PCT: Patent No. 728750) (1993-2001) at the University of Florida. Our dual-subtype FIV vaccine, released by Fort Dodge Animal Health in 2002, is the first commercial AIDS lentivirus vaccine. Developed and patented feline IL-2-independent cell lines useful for large-scale FIV production (U.S. Patent No. 5,846,825) (1994-1997). Currently receiving royalty and licensing income for both FIV diagnostics and vaccines. Donated a portion of FIV vaccine income to develop the College of Veterinary Medicine’s Comparative Clinical Immunology Program which had a faculty membership of 17 (14 tenured) in 2000. In collaboration with Dr. Ben Dunn of College of Medicine, University of Florida in 1997-2001 on the development and use of FIV/HIV-1 protease inhibitors leading to joint patent application (US Patent US6,875,773B1).

• Discovered, characterized, and patented evolutionarily conserved T-cell epitopes on FIV and HIV-1 p24 and reverse transcriptase as immunogen for HIV-1 vaccine for humans and second generation FIV vaccine for cats (Provisional Application No. 61/681,014; No. 61/684,592; 61/841,122).

Experience as Instructor, Reviewer, Speaker and Consultant • Teaching accomplishments since 1993 include served as a course coordinator of VEM Immunology 5110B (1993-2003 and 2005), giving lectures on feline AIDS & retroviruses in undergraduate, graduate, and pharmacy courses, mentoring postdoctoral fellows and graduate students, and advising and counseling of undergraduate students. Currently serving as an Affiliate Professor in the Department of Microbiology and Cell Sciences, IFAS.

Janet K. Yamamoto   • Grant reviewer in Immunology and Microbiology Section for American Heart Association (1993-1995).

• Regular member of Study Section on AIDS and Immunology for NIH, NIHM (1994-1998).

• Ad hoc regular member of Vaccine Special Emphasis Panel of AIDS and Related Research (ZRG1 VACC 01, VACC 02, VACC 03, VACC4, VACC10) (1998-2005).

• Regular member of the AIDS Immunology and Pathogenesis (AIP) Study Section Review Committee (2005-2009). Ad hoc reviewer for AIP study section (2010).

• Ad hoc reviewer for Medical Research Council and Wellcome Trust (UK), 2003, 2004, 2006, 2007, 2009, and 2015.

• Reviewer of intramural grants as member of CVM Research Committee (1993-2000, 2008- pres.).

• Ad hoc reviewer for refereed journals (AIDS, J. Immunol., AIDS Res. Hum. Retroviruses, Vaccine, J. Virol., Virology, J. Gen. Virol., Curr HIV Res, J. Retrovirology, Open AIDS J, Inf. Immun., Immunol. Today, Vaccine, Clinical Vaccine Immunol.) specializing in AIDS animal models, vaccine immunity, and cytokines in AIDS research.

• Guest speaker of a number of Universities, biotechnology companies, international and national AIDS meetings and at the World Health Organization on Animal Models of AIDS.

• Consultant on AIDS therapy, diagnostics, and animal retrovirus vaccine and therapy to number of biotechnology companies (Bio-Rad Clinical Division, Solvay R& D, Idexx Corp., Smith Kline Beecham, Kitasato Institute, Fort Dodge Animal Health, Pfizer Animal Health, R&D Systems).

CURRENT RESEARCH & GOALS:

Our research program consists of FIV prophylaxis, FIV drug and vaccine-based immunotherapy, and the use of FIV-FAIDS as a small animal model of human AIDS. Our laboratory is unique in the aspect that revenues from commercial products discovered by our laboratory also fund our research. Since January of 1985 to present, my laboratory has raised a total extramural income of $24.38 million (TDC+IDC) for the two Universities that houses/housed my laboratory. This total income consists of $8.2 million in NIH grants, $1.25 million in corporate contracts/foundation grants, and $14.8 million in patent/licensing income to the Universities (UCD & UF) of which $2.53 million of Yamamoto’s share was donated back to Yamamoto’s research at UCD and UF.

Ongoing and long-term goals of our research program are to understand the immune mechanisms of the effective prototype and commercial FIV vaccines, develop a novel vaccine approach for HIV-1 and FIV vaccines, produce species-compatible immune-therapies, bridge basic

Janet K. Yamamoto   research to clinical research, and conduct “One Medicine” by pursuing the ongoing collaborations with faculty members from College of Medicine at UF. Specific goals of current research focus are to:

1. Develop T-cell based HIV-1 vaccine for humans using novel evolutionarily conserved anti-HIV epitopes; 2. Develop an effective second-generation FIV vaccine using novel vaccine delivery system and anti-FIV T-cell epitopes;

3. Characterize the immunological and viral determinants that induce protective vaccine immunity;

4. Identify and test anti-HIV/FIV drugs in combination with therapeutic HIV/FIV vaccine (novelty lies in that the drugs and the vaccine must work on both FIV and HIV-1);

5. Develop commercial DIVA FIV diagnostic assay that differentiates FIV-infected cats from uninfected cats immunized with second-generation FIV vaccine.

INTERNATIONAL/NATIONAL SERVICES: 1991 Vaccine Section Chair, 1st Intl. Conference of Feline Retrovirus Researchers, Glasgow, UK. 1993 Immunotherapy Section Chair, 2nd Intl. Symp. Feline Retrovirus Research, Triangle Park, NC. 1992-1995 Member of Immunology and Microbiology Study Section for American Heart Association (national committee). 1994-1998 Member of Study Section on AIDS and Immunology (MHAI2) for NIH, NIHM. 1995-1996 Member of Organizing Committee, 3rd International Feline Retrovirus Research Symposium, Fort Collins, CO. 1995 Ad hoc member of Panel on RFA on Blood Brain Barrier in HIV, NIH, NIMH. 1995 Ad hoc member of Study Section on Minority enhancement program in AIDS, NIH, NIAID. 1995 Invited member of NIH, NIAID, Workshop on Live Attenuated HIV Vaccines. Rockville, MD. 1996 Ad hoc member of NIH Research Team for Wisconsin Primate Research Center Site Visit, NIH, NCRR. 1997 Vaccinology Section Chair, 2nd Intl. Feline Immunol. Workshop, Davis, CA. 1997 Invited speaker for Division of AIDS, FIV Workshop, NIH, NIAID, Rockville, MD. 1998 Ad hoc member of Study Section on Small Business and STTR Grants, NIH, NIMH. 1998 Vaccine Section Chair, 4th Intl. Feline Retrovirus Research Symp., Glasgow, UK. 1998 Ad hoc team leader of Virology and Immunology Study Section for the Southwestern Foundation Primate Research Center Site Visit, NIH, NCRR. 1998-2005 Ad hoc member of AIDS and Related Research Study Section of Vaccine Special Emphasis Panel (ZRG1 VACC 01, 02, 03, 010), NIH. 2000-2002 Chair of the Organizing Committee of 6th Intl. Feline Retrovirus Research Symp., Amelia Island, Florida. 2000 Ad hoc member of Study Section on AIDS ARR 2, NIH. 2002-pres. Member of Intl. Advisory Committee for Intl. Feline Retrovirus Research Symposium. 2002 Ad hoc member of Study Section on AIDS K08 (K08 grants), NIH.

Janet K. Yamamoto   2003-2004 Ad hoc grant reviewer for Medical Research Council, UK. 2004 Ad hoc member of Study Section on AIDS ARR 2, NIH. 2004 Vaccine Section Chair, 7th Intl. Feline Retrovirus Research Symposium, Pisa, Italy. 2005-2009 Regular member of AIDS Immunology and Pathogenesis (AIP) Study Section Review Committee, NIH, NIAID. 2006 Vaccine Section Chair, 8th Intl. Feline Retrovirus Research Symp., Washington, DC. 2006-2007 Ad hoc grant reviewer for Medical Research Council/Wellcome Trust, UK. 2008 Immunology Section Chair, 9th Intl. Feline Retrovirus Res. Symp., Vienna, Austria. 2008-2011 Member of Veterinary Immunology Committee, American Association of Immunologists (AAI). 2009 Ad hoc grant reviewer for Wellcome Trust, UK. 2009-pres. Editorial Board Member of The Open AIDS Journal. 2010 Ad hoc member of Study Section on AIP, NIAID, NIH. 2010-pres. Editorial Board Member of ISRN Veterinary Science. 2011 Grant reviewer for 2011 NIDA Avant-Garde Award for HIV/AIDS Research (X02), NIDA, NIH. 2012 Grant reviewer Innovation for HIV Vaccine Discovery (R01), NIAID, NIH. 2014 Member of R21 Cancer Immunology, ZCA1 RTRB-Z (J1) Study Section for NCI, NIH. 2014 Grant reviewer Innovation for HIV Vaccine Discovery (R01), ZAI1 BLF-A (J2)1 Study Section for NIAID, NIH. 2016 Ad hoc grant reviewer for Wellcome Trust, UK. 2016 Grant reviewer for the ZRG1 AARR-P (59) (K01 grants) Special Emphasis Panel for NIAID, NIH.

ACADEMIC SERVICES: (service as a member unless listed otherwise) Center for AIDS Research, UCD, 1985-1993. Graduate Group in Immunology, UCD, 1991-1993. Chair of Search Committee for Assistant Professor in Dept of Comp. Exp. & Path., 1993. Dept of Comp Exp & Path Committee on Department Fusion, 1993-1994. College of Veterinary Medicine (CVM) Graduate Studies Committee, 1993-1995. Graduate Co-coordinator for Dept of Infect. Dis. & Path., CVM, 1993-1995. CVM Research Committee, 1993-2000. Coordinator of Conference on Comparative Lentivirology/AIDS Research, 1994. University Senate, 1994-1995. Dept of Pathobiology, Space Committee, 1995. Dept of Pathobiology, Planning Committee, 1996-1997. Dept of Pathobiology, Ad Hoc Committee on Graduate Program for Infect Dis & Path, 1996-1997. CVM Faculty Search & Screen Committee for Professor and Chair in Dept of Pathobiology, 1997. CVM Tenure and Promotion Committee, 1999. Campus HIV Education and Policy Committee, 2000-2003. Founder & Executive Board Member of Comparative Clin. Immunology Program, CVM, 2000-2012. CVM Pentannual Review Committee for the Office of Research & Graduate Studies, 2002. Faculty Advisory Committee, Animal Care Service at the University of Florida, 2002-pres. CVM representative for the Search Committee of the Director of Emerging Pathogen Institute, 2006. Executive member of the Florida Center for AIDS Research, 2007-pres. Dept of Infect Dis & Path, Search Committee for Assistant/Associate Professor in pathology, 2008.

Janet K. Yamamoto   Dept of Infect Dis & Path, Search Committee for Assoc/Full Professor in emerging pathogens, 2008. CVM Faculty Council, 2008- 2010. CVM Research Committee, 2008. Environmental Health & Safety Committee at the University of Florida, 2008-2010. Research Policy Committee at the University of Florida, 2008-2011. Dept of Infect Dis & Path, Search Committee for Assoc/Full Professor in mol immunol, 2009- 2010. Clinical and Translational Science Institution (CTSI) Advisory Committee 2009-2010. Clinical and Translational Science Institution (CTSI) TL1 Committee 2009-pres. University Task Force on Mission Statement, 2012. University Faculty Senate, 2011-2014. CVM Research Committee 2014-pres.

UNDERGRADUATE, GRADUATE, POSTDOCTORAL AND RESEARCH TRAINING:

Major/Supervising Professor Undergraduate & Minority Trainee Projects 1991-1992 Senior Res Proj Sherry Trujillo, Dept Vet Med, Sch Vet Med, UC Davis. 1992-1993 Senior Res Proj Kelly Wang, Dept Vet Med, Sch Vet Med, UC Davis. 1992-1993 Senior Res Proj Cara Field, Dept Vet Med, Sch Vet Med, UC Davis. 1994-1995 Senior Res Proj Jeffrey Pearce, Dept Micro & Cell Sci, IFAS, UF. 1994-1995 Senior Res Proj Paul Glass, Dept Micro & Cell Sci, IFAS, UF. 1995-1996 Senior Res Proj Dena Baker, Dept Biology, Stetson University. 1995-1996 Senior Res Proj David Pollock, Dept Micro & Cell Sci, IFAS, UF. 1995-1996 Senior Res Proj John Elyar, Dept Micro & Cell Sci, IFAS, UF. 1995-1996 Senior Res Proj Ashley Zezulak, Dept Micro & Cell Sci, IFAS, UF. 1996 Senior Res Proj Carlos Laborador, Dept Micro & Cell Sci, IFAS, UF. 1996 Senior Res Proj Mimi Park, Dept Micro & Cell Sci, IFAS, UF. 1996 Senior Res Proj Saadia Haneef, Dept Zoology, UF. 1997 Senior Res Proj Christina Dietz, Dept Micro & Cell Sci, IFAS, UF. 1997-1998 Senior Res Proj Julia German, Dept Micro & Cell Sci, IFAS, UF. 1997-1999 Senior Res Proj Jessica Darman, Dept Micro & Cell Sci, IFAS, UF. (Received NIH Undergraduate Research Award. I served as sponsoring faculty for this award.) 2000-2001 Senior Res Proj Stephanie Willis, Dept Micro & Cell Sci, IFAS, UF. 1996 NIH Minority Trainee Chandi White, NIH Minority Training Program, College Med, UF. 1996 NIH Minority Trainee Nikki Hamilton, College of Vet Med, UF. 1998 NIH Minority Trainee Keawin C. Sargeant, NIH Minority Training Program, College of Med, UF. 1998 NIH Minority Trainee Allison A. Brown, NIH Minority Training Program, College of Med, UF.

Veterinary Research Projects 1988-1989 Vet Res Proj Teresa Morishita, Dept Vet Med, Sch Vet Med, UC Davis.

Janet K. Yamamoto   1993-1998 Junior Vet Res Proj Elizabeth Little, College of Vet Med, UF. 1994-1995 Junior Vet Res Proj Allison Vitsky, College of Vet Med, UF. 1994-1995 Junior Vet Res Proj Michael Mison, College of Vet Med, UF. 1996-1999 Junior Vet Res Proj Roelof Irausquin, College of Vet Med, UF. 1996-2000 Junior Vet Res Proj Nikki Hamilton, College of Vet Med, UF. 1997-2000 Junior Vet Res Proj Stacy Rine, College of Vet Med, UF. 1997-2000 Junior Vet Res Proj Barbara Lewis, College of Vet Med, UF. 1997-2000 Junior Vet Res Proj Donald Earl, College of Vet Med, UF. 1997-2000 Junior Vet Res Proj Dena Baker, College of Vet Med, UF. 1998-2000 Junior Vet Res Proj Masami Seplow, College of Vet Med, UF. 2000-2004 Junior Vet Res Proj Jay Coisman, College of Vet Med, UF. 2002-2006 Junior Vet Res Proj Glenda Parades, College of Vet Med, UF. 2011-pres Junior Vet Res Proj Mallory Offner, College of Vet Med, UF.

Postdoctoral Trainees & Visiting Associate Professor (sabbatical) 1987-1989 Postdoc. Training Takiko Okuda, DVM/MS-Japan (1982/1984); Dept Vet Med, Sch Vet Med, UC Davis. 1992-1998 Postdoc. Training Ruiyu Pu, DVM-China (1982); M.S.(1992) & Ph.D.(1995) from Dept Vet Med, UCD; Dept Pathobiology, CVM, UF. 1993-1995 Postdoc. Training Susumu Okada, DVM-Japan (1991); Dept Pathobiology, CVM, UF. 1994-1995 Postdoc. Training Jeanne Soos, PhD, Dept Pathobiology, CVM, UF. 1996-2003 Postdoc./Assist Sci Maki Arai, DVM-Japan (1996); Dept Pathobiology, CVM, UF. 1997 Postdoc. Training Marinka Tellier, PhD, Dept Pathobiology, CVM, UF. 1998-2002 Postdoc./Assist Sci Taishi Tanabe, DVM-Japan (1994); Dept Pathobiology, CVM, UF. 2001-2005 Postdoc./Assist Sci Eiji Sato, PhD, Dept Pathobiology, CVM, UF. 2007-2008 Postdoc Training Kyoko Asai, DVM/PhD-Japan (2002/2006); Dept Infectious Diseases & Pathology, CVM, UF. 2007-2013 Postdoc Training James Coleman, Dept Infectious Dis. & Pathology, CVM, UF. 2012-2014 Postdoc Training Ezra Noon-Song, Dept Infectious Dis. & Pathology, CVM, UF.

1991-1992 Visiting Assoc. Prof. Tsutomu Hohdatsu, DVM-Japan (Assoc. Prof. at Kitasato University); Dept of Vet Med, Sch Vet Med, UC Davis.

Master & Doctoral Candidates (Note *: co-sponsorship; research supervision & funding sponsored also by Yamamoto) 1989-1993 Received M.S. Howard Zochlinski, Dept Path, Sch Med, UC, Davis. (Co- Research Supervisor*) 1993-1994 Received M.S. Bin Xu, Dept Micro & Cell Sci, IFAS, UF. (Co-Research Supervisor*) 1993-1996 Received Ph.D. Marinka Tellier, Dept Pathobiology, College Vet Med, UF. 1999-2003 Received Ph.D. Mayuko Omori, Dept Pathobiology, College Vet Med, UF. 2000-2007 Received Ph.D. James Coleman, Dept Infect Dis & Path, College Vet Med, UF. 2000-2002 Received M.S. Kelley Phillips, Dept Infect Dis & Path, College Vet Med, UF. 2003-2007 Received Ph.D. Marcus Martin, Dept Micro & Cell Sci, IFAS, UF. 2009-2011 Received M.S. Yoichi Sakagawa, Dept Infect Dis & Path, Col Vet Med, UF. 9

Janet K. Yamamoto   2009-2012 Received Ph.D. Missa Sanou, Dept Micro & Cell Sci, IFAS, UF. 2011-2015 Received Ph.D. Shannon Roff, Dept Infect Dis & Path, College Vet Med, UF.

Committee Member 1993-1995 Received Ph.D. Brian E. Szente, Dept Micro & Cell Sci, IFAS, UF. 1994-1995 Received Ph.D. Nareerat Viseshakul, Dept Infect Dis, College of Vet Med, UF. 1994-1995 Received Ph.D. Barbara A. Torres, Dept Micro & Cell Sci, IFAS, UF. 1994-1999 Received Ph.D. Roberta O'Connor, Dept Pathobiology, College Vet Med, UF. 1994-1999 Received Ph.D. Leticia Reyes, Dept Pathobiology, College Vet Med, UF. 1995-1997 Received Ph.D. Amy Hobeika, Dept Micro & Cell Sci, IFAS, UF. 1995-1999 Received Ph.D. George Perrin, Dept Micro & Cell Sci, IFAS, UF. 1996-2000 Received Ph.D. Sandra Bortnik, Dept Pathobiology, College Vet Med, UF. 1996-1999 Received Ph.D. Marlene Orandle, Dept Pathobiology, College Vet Med, UF. 1997-1999 Received Ph.D. Mustafa Mujtaba, Dept Micro & Cell Sci, IFAS, UF. 1998-1999 Received M.S. Sadatoshi Maeda, Dept Small Anim Clin Sci, CVM, UF. 1998-2000 Received Ph.D. Scott Kominsky, Dept Micro & Cell Sci, IFAS, UF. 1998-2000 Received Ph.D. Joseph Larkin III, Dept Micro & Cell Sci, IFAS, UF. 2002-2004 Received Ph.D. Laurence Flowers, Dept Micro & Cell Sci, IFAS, UF. 2005-2007 Received Ph.D. Lilian Waiboci, Dept Micro & Cell Sci, IFAS, UF. 2008-2010 Received Ph.D. Lindsay Jager, Dept Micro & Cell Sci, IFAS, UF. 2008-2010 Received Ph.D. Rea Dabelic, Dept Micro & Cell Sci, IFAS, UF. 2009-2011 Received Ph.D. Ken Lau, Dept Micro & Cell Sci, IFAS, UF. 2009-2011 Received Ph.D. Ezra Noon-Song, Dept Micro & Cell Sci, IFAS, UF. 2009-2012 Received Ph.D. Erin Collins, Dept Micro & Cell Sci, IFAS, UF. 2010-2014 Received Ph.D. Tenisha Wilson, Dept Micro & Cell Sci, IFAS, UF.

International External Examiner for Ph.D. Thesis 2009 Received Ph.D. Joshua Lewis, Murdoch University, Perth, West Australia.

PROFESSIONAL, GRADUATE AND UNDERGRADUATE TEACHING: (lecturer unless designated otherwise) 1993 Course coordinator & lecturer for Veterinary Immunology VEM 5110B (16 lectures of 27- lecture course)*

1994 Course coordinator & lecturer, Veterinary Immunology VEM 5110B (16 lectures)* General Virology MCB 4503 (2 lectures) Molecular Pathogenesis VME 6464 (6 lectures)** Undergraduate Research MCB 4905: 7 credits (Summer 3 + Fall 2+2)

1995 Course coordinator & lecturer, Veterinary Immunology VEM 5110B (16 lectures)* General Virology MCB 4503 (2 lectures) Undergraduate Research MCB 4905: 15 credits (Spring 2 + Summer 3+3 + Fall 2+3+2)

Janet K. Yamamoto  

1996 Course coordinator & lecturer (16 lectures) for Veterinary Immunology VEM 5110B* General Virology MCB 4503 (3 lectures) Molecular Pathogenesis VME 6464 (6 lectures)** Undergraduate Research MCB 4905: 8 credits (Spring 2 + Fall 4+2) Undergraduate Research ZOO 4905: 3 credits (Fall 3)

1997 Course coordinator & lecturer, Vet. Immunology VEM 5110B*/VME 6905** (17 lectures) General Virology MCB 4503 (2 lectures) Undergraduate Research MCB 4905: 4 credits (Spring 2 + Fall 2)

1998 Course coordinator & lecturer, Vet. Immunology VEM 5110B*/VME 6905** (17 lectures) Molecular Pathogenesis VME 6464 (6 lectures)** General Virology MCB 4503 (2 lectures) Undergraduate Research MCB 4905: 6 credits (Spring 2 + Fall 4)

1999 Course coordinator & lecturer, Vet Immunol. VEM 5110B*/VME 6905** (16 lect + 1 lab) General Virology MCB 4503 (2 lectures) Undergraduate Research MCB 4905: 3 credits (Spring 3)

2000 Course coordinator & lecturer, Vet Immunol. VEM 5110B*/VME 6905**(16 lect + 1 Lab) Molecular Pathogenesis VME 6464 (6 lectures)** General Virology MCB 4503 (2 lectures) Undergraduate Research MCB 4905: 3 credits (Summer 3)

2001 Course coordinator & lecturer, Vet Immunol. VEM 5110B*/VME 6905**(16 lect + 1 Lab) General Virology MCB 4503 (2 lectures) Pharmacy Microbiology MCB 5252 (2 lectures)*

2002 General Virology MCB 4503 (2 lectures)

2003 Course coordinator & lecturer, Vet Immunol. VEM 5110B*/VME 6905** (8 lect + 1 Lab) General Virology MCB 4503 (2 lectures) Pharmacy Microbiology MCB 5252 (3 lectures)*

2004 ONE-YEAR SABBATICAL (no major course teaching except for the following) General Virology MCB 4503 (2 lectures in spring before sabbatical) Pharmacy Microbiology MCB 5252 (3 lectures in spring before sabbatical)*

2005 Course coordinator & lecturer, Vet Immunology VEM 5110B*/VME 6905** (13 lectures) General Virology MCB 4503 (2 lectures) Pharmacy Microbiology MCB 5252 (2 lectures)*

2006 General Virology MCB 4503 (2 lectures) Pharmacy Microbiology MCB 5252 (2 lectures)*

2007 General Virology MCB 4503 (2 lectures) 11

Janet K. Yamamoto  

2008 General Virology MCB4503 (2 lectures) Pharmacy Microbiology MCB5252 (3 lectures)* Immunology PCB5235 (2 lectures)

2009 General Virology MCB4503 (2 lectures) Immunology PCB5235 (4 lectures)

2010 General Virology MCB4503 (2 lectures) Immunology PCB5223 (4 lectures)

2011 General Virology MCB4503 (2 lectures) Immunology PCB5223 (2 lectures)

2012 General Virology MCB4503 (2 lectures) Immunology PCB5223 (1 lecture)

(*VEM 5110B required for veterinary students; *MCB 5252 for pharmacy students; **VME 6905 and VME 6464 for graduate students; MCB 4503 and PCB5235 for undergraduate students)

LECTURES TO HIGH SCHOOL STUDENTS AND TEACHERS: Sponsored by University of Florida Student Science Training Program; Yamamoto describes her academic work schedule as a professor followed by the following scientific lecture:

6/19/12 Feine immunodeficiency virus infection of cats. 6/ 22/11 Feline immunodeficiency virus: A major pathogen for cats and an animal model for HIV/AIDS. 7/21/10 Vaccines and therapeutics against feline immunodeficiency virus. 6/24/09 Feline immunodeficiency virus (FIV): FIV-cat model for HIV-1 vaccine development. 7/16/08 Feline immunodeficiency virus (FIV)-cat model: for HIV-1 vaccine development. 6/24/04 Feline immunodeficiency virus (FIV): Its discovery to vaccine development. 7/2001 Lessons from feline AIDS model.

RESEARCH FUNDING - ACADEMIC SOURCES (JKY Laboratory): 12/1/84-11/30/87 R01-CA39016, National Institutes of Health, NCI, New Investigator Research Award: Lymphokines in FeLV immunosuppression and leukemia. $107,476 TDC ($153,369 TC) (JKY, Principal Investigator).

7/1/86-6/30/88 Companion Animal Laboratory Research, School of Veterinary Medicine, UCD: 1st yr: Interferon in FeLV immunosuppression and leukemia; 2nd yr: Characterization of FIV pathogenesis and epidemiology, and the role of FIV-cat system as an animal model for human AIDS. $15,000 TDC (JKY, Principal investigator). 12

Janet K. Yamamoto  

3/1/87-2/28/90 The Robert H. Winn Foundation for Cat Research: Characterization of feline immunodeficiency virus infection. $30,000 TDC (JKY, Principal Investigator).

9/1/87-8/31/90 National Institutes of Health, NIAID: The development of FIV infection of cats as a model for HIV infection of man. $957,590 TDC ($1,363,540 TC) (JKY, Co- investigator).

7/1/89-6/30/92 R01-CA39016, National Institutes of Health, NCI: Functional & phenotypic analysis of T-cells in FIV-AIDS. $473,550 TDC ($686,647 TC) (JKY, Principal Investigator).

8/1/91-5/31/95 R01-AI030904, National Institutes of Health, NIAID: Vaccines for feline immunodeficiency virus. $585,742 TDC ($849,326 TC) (JKY, Principal Investigator).

6/1/93-5/31/94 Division of Sponsored Research, UF: Subunit envelope vaccines against feline immunodeficiency virus. $10,000 TDC for equipment (JKY, Principal Investigator).

5/1/95-4/30/96 Division of Sponsored Research, UF: Multi-subtype canarypox-based FIV vaccines: Evaluation of protective immune parameters. $20,000 TDC (JKY, Principal Investigator).

8/1/95-4/30/96 University of Tennessee subcontract: Transplantation with fractionated bone marrow cells in FIV infected cats. $3,100 TDC (JKY, Principal Investigator).

8/22/95-12/31/16* Miscellaneous Donors account: Antiretroviral prophylaxis and immunotherapeutic research. The following amounts donated from Yamamoto’s patent royalty income from UC and UF to Yamamoto’s research at UF: $25,000/year 2001, $194,000/year 2002, $226,000/year 2003, $175,000/year 2004, $211,000/year 2005, $247,000/year 2006, $232,500/year 2007, $262,150/year 2008, $294,500/year 2009, $217,000/year 2010, $125,000/year 2011, $65,000/year 2012, $130,000/year 2013, $213,000/year 2014, $102,000/year2015 TDC. The TDC for 2001-2015 is $2,717,150. (JKY, Principal Investigator)

1/1/96-12/31/00 RO1-AI030904, National Institutes of Health, NIAID: Multi-subtype FIV vaccines. $807,372 TDC ($1,166,653 TC) (JKY, Principal Investigator).

3/1/98-2/28/99 CVM Spring Consolidated Faculty Research Development Award, Autologous BMT and AZT/3TC therapies for feline AIDS, $7,470 TDC (Principal Investigator).

2/01/01-1/31/07 R01-AI030904, National Institute of Health, NIAID, Protective CMI mechanisms of a dual-subtype FIV vaccine. $1,250,000 TDC ($1,806,250 TC)

Janet K. Yamamoto   2/15/06-1/31/06 R01-AI030904 Administrative Supplement of additional $74,916 TDC ($109,003 TC) (JKY, Principal Investigator).

2/1/01-1/31/02 R01-AI030904-S, National Institute of Health, NIAID, Protective CMI mechanisms of a dual-subtype FIV vaccine. Administrative Supplement. $75,000 TDC ($108,750 TC) (JKY, Principal Investigator).

2/1/02-1/31/03 Minority Grant Supplement to R01 AI30904, National Institute of Health, NIAID, Salary support for Dr. Barbara Torres. $82,255 TDC ($119,270 TC) (Torres, Principal Investigator) (JKY, Sponsor/Mentor).

9/15/02-9/31/03 R13-AI052757, National Institute of Health, NIAID, 6th International Feline Retrovirus Research Symposium. SIFRRS Conference (Dec 2-5, 2002) grant $9,750 TDC ($14,137 TC) (JKY, Principal Investigator).

7/01/06-6/30/11 R01-AI065276-01, National Institute of Health, NIAID, HIV/FIV-cat model: a model to identify vaccine epitopes. $827,250 TDC ($1,111,625 TC) National Institute of Health, NIAID. (JKY, Principal Investigator).

07/01/08-03/31/15 R01-AI030904, National Institute of Health, NIAID, Protective CMI mechanisms of a dual-subtype FIV vaccine. Bridging fund (R56-AI30904) plus final 5-years funding $1,377,916 TDC ($1,887,125 TC) (JKY, Principal Investigator). On 2nd no cost extension as of May 1, 2014 to March 31, 2015.

09/01/09-08/30/10 R01-AI030904-S Administrative Supplement, National Institute of Health, NIAID, Protective CMI mechanisms of a dual-subtype FIV vaccine. Request for an administrative supplement to support the development of feline MHC prediction model. $51,000 TDC ($74,715 TC) (JKY, Principal Investigator).

07/01/13-06/30/18 R01 AI103348, National Institute of Health, NIAID. The structural and functional basis of HLA-associated drug hypersensitivity. (David Ostov, Principal Investigator) (JKY, Co-PI; only 3% of salary requested) (a salary saving of $5,799 to ID&P and $,2899.50 IDC ($8,698.50 TC)).

07/01/15-06/30/20 R01-AI030904-A20-A25, National Institute of Health, NIAID, Selection of protective T-cell based HIV-1/FIV vaccine devoid of viral enhancing epitopes. $2,368,043 TDC ($3,474,774 TC) (Principal Investigator, Yamamoto; Co-PIs: Drs. Mobeen Rathore and Jay A. Levy) Submitted January 7, 2015.

*Currently funded grant and account in bold

RESEARCH FUNDING - ENTREPRENEURIAL SOURCES (JKY Laboratory): 3/4/88-10/30/89 Toray Industries, Inc., Japan/UCD contracts: Dose escalation and therapeutic studies with recombinant feline interferon- on feline diseases. $62,250 TDC ($90,262 TC) (Principal Investigator).

Janet K. Yamamoto  

11/1/88-2/28/89 Bio-Rad Laboratories donation for AIDS research. $76,000 TDC in equipments (Principal Investigator).

4/27/90-4/30/91 Synbiotics Corporation, San Diego, California/UCD contract: FIV vaccines. $120,000 TDC ($174,000 TC) (Principal Investigator).

6/15/92-6/14/93 Cambridge Biotech Corporation, Worcester, Massachusetts/UCD contract: Recombinant FIV vaccines. $28,400 TDC ($41,180 TC) (Principal Investigator).

4/1/95-3/30/96 Virogenetics Corp., Troy N.Y./UF contract: Canarypox-based recombinant FIV vaccines. $30,000 TDC ($37,500 TC) (Principal Investigator).

4/27/96-1/23/97 Virogenetics Corp. (Troy, NY) / UF contract: ALVAC-FIV vaccine efficacy against FIV-Petaluma; ALVAC-FIV vaccine efficacy: follow-up reboost study. $71,926 TDC ($89,907 TC) (Principal Investigator).

6/15/98-8/31/00 Fort Dodge Animal Health (Fort Dodge, IA) / UF contract: Multi-subtype FIV vaccines: The use of Fort Dodge adjuvants. $37,450 TDC ($46,813 TC) (Principal Investigator).

7/1/98-12/31/98 Hughes Institute (St. Paul, MN) / UF contract: In vitro studies on anti-HIV agents with spermicidal activity. $8,000 TDC ($10,000) (Principal Investigator).

9/1/98-8/27/99 Hughes Institute (St. Paul, MN) / UF contract: In vivo studies on anti-HIV agents with spermicidal activity - Studies 1-3. $95,588 TDC ($119,485 TC) (Principal Investigator).

8/28/98-9/30/00 Parker Hughes Institute (St. Paul, MN) / UF contract: In vivo studies on anti- HIV agents with spermicidal activity - Study 4. $69,703.63 TDC ($87,129.54) (Principal Investigator).

2/1/01-1/31/02 Parker Hughes Institute, St. Paul, MN / UF contract: Evaluation of the tolerance, efficacy, and safety of anti-retroviral drugs in FIV-infected cats -Studies 1A. $64,825.75 TDC ($81,032.19) (Principal Investigator).

7/25/01-7/24/02 Fort Dodge Animal Health (Fort Dodge, IA) / UF contract: Evaluation of HAART therapy using a protease inhibitor and two nucleoside reverse transcriptase inhibitors in FIV-infected cats. $15,000 TDC ($18,750 TC) (Principal Investigator).

3/15/01-3/14/03 Parker Hughes Institute, St. Paul, MN / UF contract: Evaluation of the tolerance, efficacy, and safety of anti-retroviral drugs in FIV-infected cats -Studies 1B. $169,923.50 TDC ($212,404.37 TC) (Principal Investigator).

Janet K. Yamamoto   7/28/03-3/30/04 Fort Dodge Animal Health (Fort Dodge, IA) / UF contract: Clinical transmission study: Performance evaluation of an FIV vaccine under natural exposure challenge. $21,727.00 TDC ($27,158 TC) (Principal Investigator).

3/14/09-2/7/10 Pfizer Animal Health / UF contract: Pfizer AIDS vaccine trial. $112,185.74 TDC ($140,232.17 TC) (Principal Investigator).

11/13/12-7/14/13 Pfizer Animal Health / UF contract: Pfizer adjuvants for FIV vaccine trial. Phase I: $102,086.11 TDC ($127,607.64 TC); Phase II: $70,135.46 TDC ($87,669.32 TC). Combined budget: $172,221.57 TDC ($215,276.96 TC).

INTRAMURAL FUNDING, as Sponsor for Graduate or Veterinary Students or for College- wide Activity: 1/1/95-8/31/95 Division of Sponsored Research, University of Florida. Graduate student stipend (DSR-B): A novel approach to the development of a vaccine against feline immunodeficiency virus. $7,819 TDC.

9/1/95-3/1/96 Inflammatory Center, Dept. of Pathology & Laboratory Medicine, University of Florida. Graduate Assistantship: Canarypoxvirus-based FIV vaccines. $6,000 TDC.

5/28/96-7/29/96 NIH supported Short-Term Summer Research Program for Minority Students. Office of Minority Relations, College of Medicine, University of Florida. Veterinary Student Stipend and Supply Fund: $2,460.

2001 College Incentive Fund for Equipments: Gamma Irradiator. Comparative Clinical Immunology Program (Principal Investigator, Yamamoto) $21,000 TC.

6/1/01-5/31/02 Center for Immunology and Transplantation, University of Florida. Graduate Assistantship: The use of adoptive transfer system in deciphering immune mechanisms of FIV vaccine protection. $6,000 TDC (Yamamoto, Sponsor of Mayuko Omori). . 2003 CVM 2003 Merck-Merial Veterinary Scholars Research Grant. Effect of vaccination with Fel-O-Vax FIV on two week FIV post-infected and 25 week post-infected cats. Summer 2003, Student Summer stipend for veterinary student, Glenda Paredes.

9/1/09-8/31/10 CVM Division of Research and Graduate Education. Production and evaluation of pegylated recombinant feline G-CSF for treatment of neutropenic cats. $30,000 TDC (Principal Investigator, Yamamoto; Co-PI, J.R. Abbott)

Janet K. Yamamoto   12/20/10-12/19/11 CVM Division of Research and Graduate Education. Support development of recombinant feline EPO and G-CSF. $15,000 TDC (Principal Investigator, Yamamoto; Co-PI, J.R. Abbott)

5/1/12-4/30/14 University-Wide Opportunity Seed Grant. Lentivirus-specific mucosal and systemic immunity required for an effective therapeutic AIDS vaccine. $86,000 TDC (Principal Investigator, Yamamoto; Co-PIs, J Larkin III, S. Vidyasagar, L. Zhang)

* No pending intramural funding

EXTRAMURAL FUNDING, as Preceptor or Sponsor in NIH Training Grant: 7/1/95-6/30/00 T32-RR07001, National Institute of Health, NCRR: Laboratory animal medicine - comparative medicine training. $1,543,452 TDC (Principal Investigator: Dr. J.K. Davis, Dept. of Pathobiology, University of Florida)

4/15/97-4/14/02 SERCA 5K01RR00124, National Institute of Health (Mentored Research Scientist Development Award), TH1 cytokine deficiencies in cats infected with FIV. (Co-sponsors: Dr. Mary Tompkins for North Carolina State University and Dr. J.K. Yamamoto for University of Florida).

11/1/97-12/31/01 T32-CA09126, National Institute of Health, NCI: Training in cancer biology, $811,996 TDC (Principal Investigator: Dr. R. Lottenberg, Division of Hematology and Oncology, University of Florida)

EXTRAMURAL FUNDING, as Consultant: 12/1/94-11/30/99 R01-MH52527, National Institute of Health, NIMH: Peptide inhibitors of Ca++ as therapeutic agent for AIDS. $1,218,066 TDC (Principal Investigator: Dr. E.J. Blalock, University of Alabama at Birmingham) (No remuneration received as Consultant).

7/1/95-6/30/98 R01-CA69959, National Institute of Health, NCI: Structure/function studies of interferon tau. $413,000 TDC funded (Principal Investigator: Dr. H.M. Johnson, Dept. of Microbiol. & Cell Sciences, University of Florida) (No remuneration received as Consultant).

2/5/96-1/31/01 R29-HD33983-01, National Institute of Health, NICHD: Thymus pathophysiology after fetal/neonatal FIV infection, $493,651 TDC (Principal Investigator: Dr. C.M. Johnson, University of Florida) (No remuneration received as Consultant).

Janet K. Yamamoto   CORPORATE OR INSTITUTION CONSULTATIONS: The following consultations were performed as a request from either Office of Technology Transfer at University of California or Office of Technology Transfer Licensing, Division of Sponsored Research at University of Florida:

 Idexx Laboratories, Westbrook, ME on the development of a new immune cell based FIV diagnostics 2010-pres. Provide consultations under the UF Mutual Confidentiality Agreement.  Fort Dodge Animal Health, Division of American Home Products, Fort Dodge, IA on the FIV vaccine in 2000-2002. (Consultation fee donated to JKY’s Miscellaneous Donors account)  Fort Dodge Animal Health, Division of American Home Products, Fort Dodge, IA on the characterization of the FIV infected cell lines for FIV vaccines in 1997. (No consultation fee taken)  Kitasato Institute, Tokyo, Japan on the development of multi-subtype FIV vaccines in 1994- 1996. (Consultation fee donated to JKY’s Miscellaneous Donors account)  Solvay Animal Health, Inc., R & D Division, Mendota Heights, MN on the development of multi-subtype FIV vaccines in 1996. (No consultation fee taken)  SmithKline Beecham Pharmaceutical, King of Prussia, PA on the development of single- subtype FIV vaccine in 1992.  Synbiotics Corporation, San Diego, CA on the development of single-subtype FIV vaccine in 1990-1991. As a result of this consultation, I received a contract from Synbiotics in the amount of $120,000 TDC.  Idexx Laboratories, Westbrook, ME on the development of FIV diagnostics in 1987-1988. FIV diagnostics have been commercialized since 1988 and are the result of such a consultation.

The following consultations were performed as a contribution towards human diagnostics and to generate funding to facilitate my laboratory. BioRad Clinical Division donated equipments and funding which totaled to a sum of $76,000 in place of consultation fee. BioRad Chemical Division also donated BioRad equipments (preparative SDS gel electrophoresis and gene pulser).

 BioRad Clinical Division, Hercules, CA on the development of HIV immunoblot in 1988- 1989. This consultation resulted in the development of the second FDA-approved HIV immunoblot by Bio-Rad Laboratories. (No personal remuneration taken)  BioRad Chemical Division, Hercules, CA on the testing of preparative SDS gel electrophoresis products in 1991. (No personal remuneration taken)

The following consultations were performed at the request of international commission to provide update and guidance on vaccine strategies or to generate funding for our feline immunotherapy program.

 Feline AIDS Vaccine for Europe (FAVEUR)-A Concerted Action of the European Commission, UK on development and testing FIV vaccines in 1998 and 2000. (No consultation fee taken)  Schering-Plough Animal Health Corporation, Kenilworth, NJ on the use of feline interferon-omega and on potential anti-FIV drugs developed at the University of Florida in 1997 and 1999. (Consultation fee donated to Miscellaneous Donors account)

Janet K. Yamamoto   REVIEWER ON FACULTY PROMOTION:  Ad hoc reviewer of promotion packet for University of Florida in 2012 (promotion to rank of Associate Professor of Infectious Diseases and Pathology)  Ad hoc reviewer of promotion packet for University of Florida in 2009 (promotion to rank of Professor of Infectious Diseases and Pathology)   Ad hoc reviewer of promotion packet for Mississippi State University in 2009 (promotion to rank of Professor of Biological Sciences).   Ad hoc reviewer of promotion packet for Mississippi State University in 2005 (promotion to rank of Professor of Biological Sciences).   Ad hoc reviewer of promotion packet for University of California at Davis in 2005 (promotion to rank of Adjunct Professor of Medicine and Epidemiology).  Ad hoc reviewer of promotion packet for Ohio State University in 2004 (promotion to rank of Associate Professor of Veterinary Biosciences).  Ad hoc reviewer of promotion packet for University of Florida in 2002 (promotion to rank of Associate Professor of Small Animal Medicine).  Ad hoc reviewer of promotion packet for John Hopkins Medical School in 1999 (promotion to rank of Professor of Comparative Medicine).  Ad hoc reviewer of promotion packet for Texas A&M University in 1995 (promotion to rank of Professor of Veterinary Pathobiology).

OTHER NATIONAL / INTERNATIONAL ACTIVITIES:  Member of the Board of Directors, Creating Hope International (Michigan based non-profit organization to help women & children of Afghanistan), 1996-present.  NIH Alumni Society, 1998-2004.  World AIDS Marathon at Gainesville, FL, 2005.

Janet K. Yamamoto   PUBLICATIONS: Our publications are limited due to restrictions imposed by the patent and by the University patent office. US patent requires that patent application be in place not longer than one year after the first publication on the discovery; while European patents requires patent application be in place before any publication on the discovery. Therefore, we have published many of our supportive data as patent publications and not as journal publications to satisfy the patent reviewers and to minimize redundancy in work.

1. Yamamoto, J.K., J.E. Blalock, and H.M. Johnson. Human NK-like activity against mouse spleen cells. Eur. J. Immunol. 12:222-227, 1982. (5.256 JCR Impact Factor, 1997)

2. Yamamoto, J.K., W.L. Farrar, and H.M. Johnson. Interleukin 2 regulation of mitogen induction of immune interferon (IFN) in spleen cells and thymocytes. Cell. Immunol. 66:333-341, 1982. (1.830 JCR Impact Factor, 1997)

3. Torres, B.T., J.K. Yamamoto, and H.M. Johnson. Cellular regulation of immune interferon (IFN) production: Lyt phenotype of the suppressor cell. Infect. Immun. 35:770-776, 1982. (3.713 JCR Impact Factor, 1997)

4. Swain, S.L., R.W. Dutton, R. Schwab, and J. Yamamoto. Xenogeneic human anti-mouse T cell responses are due to the activity of the same functional T cell subsets responsible for allospecific and major histocompatibility complex-restricted responses. J. Exp. Med. 157:720- 729, 1983. (14.384 JCR Impact Factor, 1997)

5. Carlson, J., S. Hinrichs, M. Bryant, N. Levy, J. Yamamoto, J. Yee, M. Gardner, J. Higgins, N.C. Pedersen, and P. Holland. HTLV-III antibody screening of blood bank donors. Lancet 1:523-524, 1985. (16.135 JCR Impact Factor, 1997)

6. Carlson, J.R., M.L. Bryant, S.H. Hinrichs, J.K. Yamamoto, N.B. Levy, J. Yee, J. Higgins, A.M. Levine, P. Holland, M.B. Gardner, and N.C. Pedersen. AIDS serology testing in low- and high-risk groups. JAMA 253:3405-3408, 1985. (9.258 JCR Impact Factor, 1997)

7. Munn, R.J., P.A. Marx, J.K. Yamamoto, and M.B. Gardner. Ultrastructural comparison of the retroviruses associated with human and simian acquired immunodeficiency syndromes. Lab. Invest. 53:194-199, 1985. (4.653 JCR Impact Factor, 1997)

8. Bryant, M.L., J.K. Yamamoto, P. Luciw, R. Munn, P. Marx, J. Higgins, N. Pedersen, A. Levine, and M.B. Gardner. Molecular comparison of retroviruses associated with human and simian AIDS. Hematol. Oncol. 3:187-198, 1985. (0.711 JCR Impact Factor, 1997)

9. Yamamoto, J.K., E. Ho, and N.C. Pedersen. A feline retrovirus induced T-lymphoblastoid cell-line that produces an atypical alpha type of interferon. Vet. Immunol. Immunopath. 11:1- 19, 1986. (0.867 JCR Impact Factor, 1997)

Janet K. Yamamoto   10. Yamamoto, J.K., F. Barré-Sinoussi, V. Bolton, N.C. Pedersen, and M.B. Gardner. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J. Interferon Res. 6:143-152, 1986. (1.471 JCR Impact Factor, 1997)

11. Pedersen, N.C., E.W. Ho, M.L. Brown, and J.K. Yamamoto. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790-793, 1987. (24.676 JCR Impact Factor, 1997)

12. Pedersen, N.C., E.W. Ho, M.L. Brown, and J.K. Yamamoto. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Veterinaria 1, 1987, 15- 22. (0.148 JCR Impact Factor, 2009)

13. Pedersen, NC, E. Sparger, J.K. Yamamoto, H. Lutz, T. Ishida, T, M. Girard. (ed. Valette, L.) Feline T-lymphotropic lentivirus infection of cats: a small laboratory animal model for HIV infection. In: Retroviruses of Human A.I.D.S. and Related Animal Diseases. Septieme Colloque Des Cent Gardes. Vol. 2. pp. 177-180, M. Girard and L. Valette, eds. Fondation Marcel Merieux, Lyon, France. 1987. (book)

14. Yamamoto, J.K., N.C. Pedersen, E.W. Ho, T. Okuda and G.H. Theilen. Feline immunodeficiency syndrome - a comparison between feline T- lymphotropic lentivirus and feline leukemia virus. Leukemia, Dec. Suppl. 2:204S-215S, 1988. (3.227 JCR Impact Factor, 1997)

15. Yamamoto, J.K., E. Sparger, E.W. Ho, P.H. Andersen, T.P. O'Connor, C.P. Mandell, L. Lowenstine, and N.C. Pedersen. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am. J. Vet. Res. 49:1246-1258, 1988. (1.148 JCR Impact Factor, 1997)

16. Sparger, E.E. and J.K. Yamamoto. Feline immunodeficiency virus infection. Chapter 4. In: Current Veterinary Therapy. R.W. Kirk, ed. W.B. Saunder Co., Ithica, NY. p. 530-4, 1989.

17. Yamamoto, J.K., H. Hansen, E.W. Ho, T.Y. Morishita, T. Okuda, T.R. Sawa, R.M. Nakamura, and N.C. Pedersen. Epidemiologic and clinical aspects of feline immunodeficiency virus (FIV) infection in cats from the continental United States and Canada and possible mode of transmission. J. Am. Vet. Med. Assoc. 194:213-220, 1989. (0.948 JCR Impact Factor, 1997)

18. O'Connor, T.P., S. Tanguay, R. Steinman, R. Smith, M.C. Barr, J.K. Yamamoto, N.C. Pedersen, P.R. Andersen, and Q.J. Tonelli. Development and evaluation of immunoassay for detection of antibodies to the feline T-lymphotropic lentivirus (feline immunodeficiency virus). J. Clin. Microbiol. 27:474-479, 1989. (3.783 JCR Impact Factor, 1997)

19. Olmsted, R.A., A.K. Barnes, J.K. Yamamoto, V.M. Hirsch, R.H. Purcell, and P.R. Johnson. Molecular cloning of feline immunodeficiency virus. Proc. Nat. Acad. Sci. 86:2448-2452, 1989. (9.040 JCR Impact Factor, 1997)

20. Pedersen, N.C., J.K. Yamamoto, T. Ishida, and H. Hansen. Feline immunodeficiency virus infection. Vet. Immunol. Immunopath. 21:111-129, 1989. (0.867 JCR Impact Factor, 1997) 21

Janet K. Yamamoto  

21. Sparger, E.E., P.A. Luciw, J.H. Elder, J.K. Yamamoto, L.J. Lowenstine, and N.C. Pedersen. Feline immunodeficiency virus is a lentivirus associated with an AIDS-like disease in cats. AIDS 3 (suppl.):S43, 1989. (5.050 JCR Impact Factor, 1997)

22. Pedersen, N.C., M. Torten, B. Rideout, E. Sparger, T. Tonachini, P.A. Luciw, C. Ackley, N. Levy, and J.K. Yamamoto. Feline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection. J. Virol. 64:598-606, 1990. (5.821 JCR Impact Factor, 1997)

23. Ackley, C.D., J.K. Yamamoto, N.B. Levy, N.C. Pedersen, and M.D. Cooper. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J. Virol. 64:5652-5655, 1990. (5.821 JCR Impact Factor, 1997)

24. Jarrett, O., J.K. Yamamoto, and J.C. Neil. Feline immunodeficiency virus as a model for AIDS vaccination. AIDS 1990. 5(suppl 1):S163-S165, 1991. (5.050 JCR Impact Factor, 1997)

25. Yamamoto, J.K., C.D. Ackley, H. Zochlinski, H. Louie, E. Pembroke, M. Torten, H. Hansen, R. Munn, and T. Okuda. Development of IL 2 independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirol. 32:361-375, 1991. (0.787 JCR Impact Factor, 1997)

26. Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Louie, H. Zochlinski, E. Pembroke, and M.B. Gardner. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retroviruses. 7:911-922, 1991. (3.069 JCR Impact Factor, 1997)

27. Yamamoto, J.K. and R.J. Munn. Isolation of a FAIDS upregulated protein from infected feline lymphoid cell lysates by preparative SDS gel electrophoresis. Bio Rad US/EG Bulletin 1686, 1991.

28. Gardner, M., J. Yamamoto, M. Marthas, C. Miller, M. Jennings, A. Rosenthal, P. Luciw, V. Planelles, T. Yilma, L. Giavendoni, S. Ahmed, K. Steimer, N. Haigwood, and N. Pedersen. SIV and FIV vaccine studies at UC Davis: 1991 update. AIDS Res. Hum. Retroviruses. 8:1495-1498, 1992. (3.069 JCR Impact Factor, 1997)

29. Yamamoto, J.K. and M.B. Gardner. Feline immunodeficiency virus - a model for AIDS vaccine. In: Retroviruses of Human A.I.D.S. and Related Animal Diseases. Septieme Colloque Des Cent Gardes. Vol. 7. pp. 251-257, M. Girard and L. Valette, eds. Fondation Marcel Merieux, Lyon, France. 1992. (book)

30. Yamamoto, J.K., T. Hohdatsu, R. A. Olmsted, R. Pu, H. Louie, H. Zochlinski, V. Acevedo, H.M. Johnson, G.A. Soulds, and M.B. Gardner. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol. 67:601-605, 1993. (5.821 JCR Impact Factor, 1997)

Janet K. Yamamoto   31. Hohdatsu, T., R. Pu, B.A. Torres, S. Trujillo, M.B. Gardner, and J.K. Yamamoto. Passive protection of cats against feline immunodeficiency virus infection. J. Virol. 67:2344-2348, 1993. (5.821 JCR Impact Factor, 1997)

32. Yamamoto, J.K., M.L. Kruzel, H. Louie, and J.A. Georgiades. Inhibition of human immunodeficiency virus type 1 replication by human interferons alpha, beta and gamma. Archivum Immunologiae et Therapiae Experimentalis. 41:185-191, 1993. (0.793 JCR Impact Factor, 2002)

33. Johnson, C.M., B.A. Torres, H. Koyama, and J.K. Yamamoto. FIV as a model for AIDS vaccination. AIDS Res. Hum. Retroviruses. 10:225-228, 1994. (3.069 JCR Impact Factor, 1997)

34. Okada, S., R. Pu, E. Young, W. Stoffs, and J.K. Yamamoto. Superinfection of cats with FIV Subtypes A and B. AIDS Res. Hum. Retroviruses. 10:1739-1746, 1994. (3.069 JCR Impact Factor, 1997)

35. Pu, R., S. Okada, E.R. Little, B. Xu, W.V. Stoffs, and J.K. Yamamoto. Protection of neonatal kittens against FIV infection with passive maternal antibodies. AIDS. 9:235-242, 1995. (5.050 JCR Impact Factor, 1997)

36. Hosie, M.J. and J.K. Yamamoto. Vaccination against FIV infection. In: Feline Immunology and Immunodeficiency. B.J. Willett and O. Jarrett, eds. Oxford University Press, p.263-278, 1995. (book)

37. Hosie, M.J., R. Osborne, F.J. Thompson, J.K. Yamamoto, J.C. Neil, and O. Jarrett. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 69:1253-1255, 1995. (5.821 JCR Impact Factor, 1997)

38. Kakinuma, S., K. Motokawa, T. Hohdatsu, J.K. Yamamoto, H. Koyama, and H. Hashimoto. Nucleotide sequence of feline immunodeficiency virus: classification of Japanese isolate into two subtypes which are distinct from non-Japanese subtypes. J. Virol. 69:3639-3646, 1995. (5.821 JCR Impact Factor, 1997)

39. Torres, B.A., T. Tanabe, J.K. Yamamoto, and H.M. Johnson. HIV encodes for its own CD4 T cell superantigen mitogen. BBRC 225:672-678, 1996. (2.671 JCR Impact Factor)

40. Pontzer, C.H., J.K. Yamamoto, T.L. Ott, F.W. Bazer, and H.M. Johnson. Potent anti-feline immunodeficiency virus and anti-human immunodeficiency effect of interferon tau. J. Immunol. 158:4351-4357, 1997. (6.937 JCR Impact Factor)

41. Pu, R., M.C. Tellier, and J.K. Yamamoto. Mechanism of FIV vaccine protection. Leukemia. 11(S3):98-101, 1997. (3.227 JCR Impact Factor)

Janet K. Yamamoto   42. Elyar, J., M.C. Tellier, J.M. Soos, and J.K. Yamamoto. Perspectives on FIV vaccine development. Vaccine 15:1437-1444, 1997. (1.949 JCR Impact Factor)

43. Tellier, M.C., J.M. Soos, R. Pu, D. Pollock, and J.K. Yamamoto. Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunization with FIV vaccines. Vet. Microbiol. 57:1-11, 1997. (1.251 JCR Impact Factor)

44. Torres, B.A., S. Okada, J. Elyar, and J.K. Yamamoto. Fundamentals of FIV infection: Is a vaccine possible? Feline Pract. 26:2-9, 1997. (0.760 JCR Impact Factor)

45. Gengozian, N., L. Reyes, R. Pu, B.L. Homer, F.J. Bova, and J.K. Yamamoto. Fractionation of feline bone marrow with the soybean agglutinin lectin yields populations enriched for erythroid and myeloid elements: Transplantation of soybean agglutinin negative cells into lethally irradiated recipients. Transplantation 64:510-518, 1997. (3.441 JCR Impact Factor)

46. Hohdatsu, T., S. Okada, K. Motokawa, J.K. Yamamoto, and H. Koyama. Effect of dual- subtype vaccine against feline immunodeficiency virus infection. Vet. Microbiol. 58:155-165, 1997. (1.251 JCR Impact Factor)

47. Tellier, M.C., R. Pu, D. Pollock, A. Vitsky, T. Tartaglia, E. Paoletti, and J.K. Yamamoto. Efficacy evaluation of prime/boost protocol: Canarypox-based (ALVAC) FIV recombinant and inactivated FIV-cell vaccine against heterologous FIV challenges in cats. AIDS 12:11-18, 1998. (6.109 JCR Impact Factor)

48. Torres, B.T. T. Tanabe, P.S. Subramaniam, J.K. Yamamoto, and H.M. Johnson. Mechanism of HIV pathogenesis: Role of superantigens in disease. Alcoholism: Clin. Exp. Res. 22:188S- 192S, 1998.

49. Pu, R. and J.K. Yamamoto. Passive transfer of immunity. In: Handbook of Vertebrate Immunology. Pastoret, P.P. (Ed). Academic Press Ltd, London. p. 305-308, 1998. (book)

50. Elder, J.H., G.A. Dean, E.A. Hoover, J.A. Hoxie, M.H. Malim, L. Mathes, J.C. Neil, T.W. North, E. Sparger, M.B. Tompkins, W.A.F. Tompkins, J. Yamamoto, N. Yuhki, N.C. Pedersen, and R.H. Miller. Workshop Summary: Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:797-801, 1998. (2.609 JCR Impact Factor)

51. Yamamoto, J.K., R. Pu, M. Arai, D. Pollock, R. Irausquin, F.J. Bova, L. Fox, B.L. Homer, and N. Gengozian. Feline bone marrow transplantation: Its use in FIV-infected cats. Vet. Immunol. Immunopath. 65:323-351, 1998. (1.138 JCR Impact Factor)

52. Yamamoto, J.K. Feline immunodeficiency virus (Retroviridae). In: Encyclopedia of Virology, 2nd Ed. R.G. Webster and A. Granoff (Eds), Academic Press Ltd, London, p. 535- 541, 1999. (book)

53. Pu, R., S. Okada, M. Omori, S.L. Rine, B.A. Lewis, E. Lipton, L. Nemcik, P. Glass, and J.K. Yamamoto. MHC-restricted protection of cats against FIV infection by adoptive transfer of 24

Janet K. Yamamoto   immune cells from FIV-vaccinated donors. Cell. Immunol. 198:30-43, 1999. (2.252 JCR Impact Factor)

54. Arai, M., J. Darmen, A. Lewis, and J.K.Yamamoto. The use of human hematopoietic growth factors (rhGM-CSF and rhEPO) as a supportive therapy for FIV-infected cats. Vet. Immunol. Immunopath. 77:71-92, 2000. (1.343 JCR Impact Factor)

55. Jacobson, E.R., J. Oros, S. Tucker, D. Pollock, K. Vaughn, R.J. Munn, B. Lock, A. Mergia, and J.K. Yamamoto. Isolation and characterization of retroviruses from Boid snakes with inclusion body disease. Am. J. Vet. Res. 62:217-224, 2001. (1.040 JCR Impact Factor)

56. Tanabe, T. and J.K. Yamamoto. Phenotypic and functional characterization of FIV infection in bone marrow stroma. Virology 282:113-122, 2001. (3.270 JCR Impact Factor)

57. Pu, R., J. Coleman*, M. Omori, M. Mison, C. Huang, M. Arai, T. Tanabe, and J.K. Yamamoto. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15:1225-1237, 2001. (*Coleman and Pu contributed equally and they are co-first authors) (6.881 JCR Impact Factor)

58. Maeda, S., T. Miyabayshi, J.K. Yamamoto, G.D. Roberts, A.J. Lepine, and R.M. Clemmons. Quantitative analysis of chondroitin sulfate isomers in intervertebral disk chondrocyte culture using capillary electrophoresis. J. Vet. Med. Sci. 63:1039-1043, 2001. (0.533 JCR Impact Factor)

59. Tanabe, T. and J.K. Yamamoto. Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline interferon-. J. Interferon Cytokine Res. 21:1039-1046, 2001. (2.281 JCR Impact Factor)

60. Arai, M., D. Earle, and J.K. Yamamoto. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet. Immunol. Immunopath. 85:189-204, 2002. (1.659 JCR Impact Factor)

62. Uhl, E.W., T. Heaton-Jones, R. Pu, and J.K. Yamamoto. FIV vaccine development and its importance to veterinary and human medicine: a review. Vet. Immunol. Immunopath. 90:113- 132, 2002. (1.659 JCR Impact Factor)

63. Yamamoto, J.K., B.A. Torres, and R. Pu. Development of the dual-subtype FIV vaccine. AIDScience Vol. 2, No. 8, April 2002 (http://aidscience.org/Articles/AIDScience020.asp).

64. Maeda, S., T. Miyabayshi, J.K. Yamamoto, G.D. Roberts, A.J. Lepine, and R.M. Clemmons. Temporal dynamic changes in synthesis of chondroitin sulfate isomers in canine articular chondrocyte culture. . J. Vet. Med. Sci. 65:1373-1376, 2003. (0.627 JCR Impact Factor)

65. Omori, M., R. Pu, T. Tanabe, W. Hou, J. Coleman, M Arai, and J.K. Yamamoto. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine 23:386-398, 2004. (2.824 JCR Impact Factor)

Janet K. Yamamoto

 66. Pu, R., G. Paredes, and J.K. Yamamoto. FIV vaccine update. Am. Assoc. Feline Practitioners proceeding, pp. 103-107, 2004.

67. Pu, R., E. Sato, J. Coisman, J.K. Coleman, T. Tanabe, M. Arai, and J.K. Yamamoto. Dual- subtype FIV vaccine (Fel-O-Vax® FIV) protection against a heterologous subtype B FIV isolate. J. Feline Med. Surg. 7:65-70, 2005. (1.137 JCR Impact Factor)

68. Phillips, K., M. Arai, T. Tanabe, R. Raskin, M. Volz, E.W. Uhl, and J.K. Yamamoto. FIV- infected cats respond to short-term rHuG-CSF treatment which results in anti-rHuG-CSF neutralizing antibody production that inactivates drug activity. Vet. Immunol. Immunopath. 108:357-371, 2005. (1.626 JCR Impact Factor)

69. Coleman, J.K., R. Pu, M. Martin, E. Sato, and J.K. Yamamoto. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. AIDS 19:1457-1466, 2005. (5.835 JCR Impact Factor)

70. Yamamoto, J.K., E. Sato, R. Pu, J. Coleman, and M. Martin. Feline immunodeficiency virus vaccines: evolving concepts in vaccine approaches. Cellscience Reviews Vol. 2, No. 3, Jan. 2006. (http://www.cellscience.com/reviews7/Feline_immunodeficiency_virus_vaccines.html).

71. Yamamoto, J.K., R. Pu, E. Sato, and T. Hohdatsu. FIV pathogenesis and development of a dual-subtype FIV vaccine. AIDS 21:547-563, 2007. (5.842 JCR Impact Factor)

72. Zwijnenberg R, Yamamoto, J.K. Vaccine protection against feline immunodeficiency virus: setting the challenge. Aust. Vet. J. 85(6):210, 2007. (0.581 JCR Impact Factor)

73. Yamamoto, J.K. Bovine and feline immunodeficiency viruses. In: Encyclopedia of Virology. 3rd Ed. B. Hahy and M Van Regenmortel (Eds), Elsevier Ltd, Oxford, UK, p. 347-354, 2008. (book)

74. Uhl, E.W., M. Martin, J. Coleman, and J.K. Yamamoto. Advances in FIV vaccine technology. Vet. Immunol. Immunopath. 123:65-80, 2008. (1.907 JCR Impact Factor)

75. Yamamoto, J.K. Evolving perspectives on FIV vaccines. Practitioner’s Update: Feline Retrovirus Disease, 1:4-7, 2009.

76. Yamamoto, J.K., M.P. Sanou, J.R. Abbott, and J.K. Coleman. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res. 8:14-25, 2010. (1.923 JCR Impact Factor)

77. Abbott, J.R., M.P. Sanou, J.K. Coleman, and J.K. Yamamoto. Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine. Vet. Immunol. Immunopathol 143:246- 254, 2011. (2.076 JCR Impact Factor)

Janet K. Yamamoto

 78. Abbott, J.R., R. Pu, J.K. Coleman, and J.K. Yamamoto. Utilization of feline ELISPOT for mapping vaccine epitopes. Chapter 4, Handbook for ELISPOT: Methods and Protocols, 2nd Ed., A.E. Kalyuzhny (Ed), Humana Press, Methods Mol. Biol. 792:47-63, 2012. (book)

79. Sanou, M.P., A.S. De Groot, M. Murphey-Corb, J.A. Levy, and J.K. Yamamoto. HIV-1 vaccine trials: evolving concepts and designs. The Open AIDS. 6:274-288, 2012.

80. Coleman, J.K., P. Pu, M.M. Martin, E.N. Noon-Song, R. Zwijnenberg, and J.K. Yamamoto. Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies. Vaccine 32:746-754, 2014. PubMed, doi: 10.1016/j.vaccine.2013.05.024 (3.624 JCR Impact Factor)

81. Sanou, M.P., S. Roff, A. Mennella, J.W. Sleasman, M.H. Rathore, J.K. Yamamoto* and J.A. Levy. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. J Virol. 87:10004-10015, 2013; DOI: 10.1128/JVI.00359-13. (*Corresponding author) (4.648 JCR Impact Factor)

82. Roff, S.R., E.N. Noon-Song, and J.K. Yamamoto. The significance of interferon-γ in HIV-1 pathogenesis, therapy, and prophylaxis. Front. Immunol. Vol. 4, article 498, online on January 13, 2014; DOI: 10.3389/fimmu.2013.00498.

83. Coleman J.K.*,Y. Sakagawa,*, E.N. Noon-Song, T. Tanabe, M.J. Offner, J.G. Coisman, S.R. Roff, H. Kondo, J.K. Yamamoto**, and J.R. Abbott. Pegylated feline granulocyte colony- stimulating factor increases neutrophil levels in cats. Veterinary J. 200(1):44-50. doi: 10.1016/j.tvjl.2014.01.019. (*Sakagawa and Coleman contributed equally and they are co-first authors; **Corresponding author) (1.693 JCR Impact Factor, 2014)

84. Roff S.R., M.P. Sanou, M.H. Rathore, J.A. Levy, and J.K. Yamamoto. Conserved epitopes on HIV-1, SIV, and FIV p24 proteins are recognized by HIV-1 infected subjects. Human Vaccines & Immunotherapeutics, 11(6):1540-1556, 2015. (2.366 JCR Impact Factor, 2014)

85. Aranyos A.M.*, S.R. Roff *, R. Pu, J.L. Owen, J.K. Coleman, and J.K. Yamamoto. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection. (*Aranyos and Roff contributed equally and they are co-first authors.) Vaccine 34:1480-1488, 2016. doi: 10.1016/j.vaccine.2016.01.017. (3.624 JCR Impact Factor, 2014)

86. Yamamoto J.K., M.P. Sanou, M.H. Rathore. Reconsidering the importance of T-cell immunity for an effective HIV vaccine. (review in preparation for Current HIV Research).

87. Yamamoto J.K., A.M.Aranyos, R. Pu, S.R. Roff, M.P. Sanou, J.L. Owen, R.H. Rathore. Immunogenicity and protective efficacy of multiple antigenic peptides against pathogenic feline immunodeficiency virus. (in preparation for PNAS)

Janet K. Yamamoto

 88. Aranyos A.M., E.N., Noon-Song, E. Sato, and J.K. Yamamoto. Breeding of feline leukocyte antigen matched cats. (in preparation for Immunogenetics)

89. Roff S.R., A.M. Aranyos, R. Pu, J.L. Owen, W.M. Zoll, and J.K. Yamamoto. Thyroid hypertrophy in cats infected with highly pathogenic feline immunodeficiency virus. (in preparation for Vet Pathol)

OTHER PUBLICATIONS (Including Patent Publications): Sixty % of the original patent applications of the University of California was written by me, while the remaining portion was written by the patent lawyers (patent publications 2-6). We have been fortunate at the University of Florida to have patent lawyers accessible for direct consultation, which decreased my time spent on patent publications to 20-35% per patent (patent publications 8, 10-34). All patents were supported by the Universities, except for patent publication #17, which was supported by my patent income.

1. Yamamoto, J.K. Xenogeneic interactions in the expression of human lymphocyte functions. Ph.D. Dissertation, The University of Texas Medical Branch at Galveston, 1981.

2. Pedersen, N.C. and J.K. Yamamoto. Oncornavirus vaccines and feline alpha-type interferon (this discovery includes interferon-omega). United States Patent Application No. 882,088 filed on July 3, 1986. United States Patent No. 4,861,720 issued August 29, 1989.

3. Pedersen, N.C. and J.K. Yamamoto. Feline T-lymphotropic lentivirus. United States Patent Application No. 618,030 filed on November 16, 1990. United States Patent No. 5,037,753A issued on August 6, 1991.

4. Pedersen, N.C. and J.K. Yamamoto. Feline T-lymphotropic lentivirus assay. United States Patent Application No. 614,474 filed on November 16, 1990. United States Patent No. 5,118,602A issued on June 2, 1992.

5. Yamamoto, J.K. and N.C. Pedersen. Methods and compositions for vaccinating against feline immunodeficiency virus. United States Patent Application No. 739,014 filed on July 31, 1991. United States Patent No. 5,275,813A issued on January 4, 1994.

6. Yamamoto, J.K. and N.C. Pedersen. Methods and compositions for vaccinating against feline immunodeficiency virus (additional patent coverage to US Patent No. 5,275,813). United States Patent No. 5,510,106A issued on April 23, 1996.

7. Johnson, H.M., B.A. Torres, and J.K. Yamamoto. Retroviral superantigen, superantigen peptide, and method of use. United States Patent No. 5,519,114 issued on May 21, 1996.

8. Yamamoto, J.K. Feline derived T-cell lines for producing FIV. United States Patent Application No. 841,238 filed on April 29, 1997. United States Patent No. 5,846,825A issued on December 8, 1998.

Janet K. Yamamoto



9. Johnson, H.M., B.A. Torres, and J.K. Yamamoto. (Patent written by Dr. Johnson) Methods for stimulating immune responses in host through the administration of superantigen peptides derived from human immunodeficiency virus type 1 nef. United States Patent Application No. 08/331,454 filed on October 31, 1994. United States Patent No. 5,968,514 issued on Oct. 19, 1999.

10. Yamamoto, J.K. Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccine. United States Patent Application No. 07/995,304 filed on December 21, 1992. United States Patent No. 6,107,077 issued on August 22, 2000. (currently receiving licensing income)

11. Yamamoto, J.K. Multi-subtype FIV vaccines. United States Patent Application No. 09/025,610 filed on February 18, 1998. United States Patent No. 6,254,872B1 issued on July 3, 2001. The inventor’s shares of the patent/licensing incomes have been donated to the inventor’s research for development of novel immunotherapy and to establish the Comparative Clinical Immunology Program for the Department of Infectious Diseases and Pathology and the College of Veterinary Medicine. (currently receiving licensing income)

12. Yamamoto, J.K. Multi-subtype FIV vaccines. United States Patent Application No. 09/512,746 filed on October 1, 1997. United States Patent No. 6,447,993B1 issued on September 10, 2002. This patent provides additional coverage to the previous U.S. Patent No. 6,254,872B1 and includes additional data on the cell-type tropisms of the vaccine viruses. This patent provides additional claims covering the enhancement of immunogenicity in host animal against FIV when immunized with a vaccine composed of plurality of FIV subtypes in form of FIV virus or an FIV-infected cell line. (currently receiving licensing income)

13. Yamamoto, J.K. Multi-subtype FIV vaccines. United States Patent Application No. 09/707,532 filed on November 7, 2000. United States Patent No. 6,544,528B1 issued on issued April 8, 2003. (currently receiving licensing income)

14. Yamamoto, J.K., Jennifer White Janelle, Barbara Aurea Torres, Maki Arai, Taishi Tanabe, and Ruiyu Pu. Materials and methods for detecting, preventing and treating retroviral infection. U.S. Provisional Patent Application No. 60/270,745 filed on February 22, 2001; United States Patent Application No. 10/080,772 filed on February 22, 2002. United States Patent Application Publication No. US 2003/00911987 A1 published on May 15, 2003.

15. Yamamoto, J.K. Multi-subtype FIV vaccines. United States Patent Application No. 10/116,196 filed on April 3, 2002. United States Patent No. 6,605,282B2 issued on issued August 12, 2003. (currently receiving licensing income)

16. Yamamoto, J.K. Multi-subtype FIV vaccines. Australian Patent Application No. 19725/01 filed on August 23, 1996. Australian Patent No. 772,353 issued September 2, 2004. (currently receiving licensing income)

Janet K. Yamamoto

 17. Dunn, B.M., J.K. Yamamoto, and M. Arai. Combination therapy for treatment of FIV infection. United States Application No. 09/763,037 filed on May 28, 1998. United States Patent No. 6,875,773 B1 issued on April 5, 2005.

18. Yamamoto, J.K. Multi-subtype FIV vaccines. European Patent Application No. 96928989.1 filed on August 23, 1996. European Patent No. EP 0 848 615 B1 (Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland) issued on June 8, 2005.

19. Yamamoto, J.K. Multi-subtype FIV vaccines. Korean Patent Application No. 2004-7003434 filed on August 23, 1996. Korean Patent No. 0502568 issued on July 12, 2005.

20. Yamamoto, J.K. Multi-subtype FIV vaccines. Polish Patent Application P-358,248 filed on August 23, 1996. Polish Patent No. 188,041 issued on January 18, 2006.

21. Yamamoto, J.K. Treating using multi-subtype FIV vaccines. New Zealand Patent Application No. 513,388 filed on August 23, 1996. New Zealand Patent No. 513388 issued on June 8, 2006. (currently receiving licensing income)

22. Yamamoto, J.K. Multi-subtype feline immunodeficiency virus (FIV) vaccines. Israeli Patent Application No. 123264 filed on August 23, 1996. Israeli Patent No. 123264 issued December 6, 2006.

23. Yamamoto, J.K. IL-2 independent feline-derived T-cells. European Patent Application No. 00111079.0 filed on August 23, 1996. European Patent No. EP 1 090985 B1 (Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland) issued August 9, 2006.

24. Yamamoto, J.K. Multi-subtype FIV vaccines. Mexican Patent Application No. PA/a/1998/001570 filed on August 23, 1996. Mexican Patent No. 243130 issued on January 8, 2007.

25. Yamamoto, J.K. Materials and methods for immunizing against FIV infection. South African Patent Application No. 2005/08853 filed May 12, 2004. South African Patent No. 2005/8853 issued on February 28, 2007.

26. Yamamoto, J.K. IL-1 independent feline-derived cells. Hong Kong Application No. 01107137.8, filed August 23, 1996. Hong Kong Patent No. HK1038584 issued on September 7, 2007.

27. Yamamoto, J.K. Multi-subtype FIV vaccines. United States Patent Application No. 10/408,701 filed on April 7, 2003. United States Patent No. 7,267,824B2 issued on issued September 11, 2007. (currently receiving licensing income)

Janet K. Yamamoto

 28. Yamamoto, J.K. Multi-subtype FIV vaccines. United States Patent Application No. 10/636,079 filed on August 6, 2003. United States Patent No. 7,311,921B2 issued on issued December 25, 2007. (currently receiving licensing income)

29. Yamamoto, J.K. Materials and methods for immunizing against FIV infection. Chinese Patent Application No. 200480018243.2 filed May 12, 2004. Chinese Patent No. 2004 8 0018243.2 issued on May 14, 2008.

30. Yamamoto, J.K. Multi-subtype FIV vaccines. Mexican Patent Application No. PA/a/2003/003079 filed on August 23, 1996. Mexican Patent No. 255708 issued on March 28, 2008.

31. Yamamoto, J.K. Multi-subtype FIV vaccines. Japanese Patent Application No. Hei09-510430 filed on August 23, 1996. Japanese Patent 4,142,741 issued on June 20, 2008. (currently receiving licensing income)

32. Yamamoto, J.K. HIV/SIV/FIV Cross-Reactive T-Cell Epitopes (on p24) for Vaccines in Humans. U.S. Provisional Application No. 61/681,014 for p24 filed on 08/08/2012.

33. Yamamoto, J.K. HIV/SIV/FIV Cross-Reactive T-Cell Epitopes (on p24) for Vaccines in Humans and Cats. U.S. Provisional Application No. 61/684,592 for p24 filed on 08/17/2012.

34. Yamamoto, J.K. Evolutionarily Conserved Epitopes on HIV-1 and FIV Reverse Transcriptases Detected By HIV-1-Infected Subjects. U.S. Provisional Application No. 61/841,122 filed on 06/28/2013.

35. Yamamoto, J.K. Vaccine Peptide Epitopes on HIV-1 and FIV Matrix, Nucleocapsid, Integrase, Protease, Transmembrane Envelope, and Surface Envelope. Provisional Application No. 15849UF filed on 07/16/2015.

ABSTRACTS & ORAL PRESENTATIONS AT INTERNATIONAL OR NATIONAL MEETINGS: (over 30 local presentations not included)

1. Yamamoto, J.K. and H.M. Johnson. Human peripheral lymphocytes possess suppressor activity in an in vitro xenogeneic system. Fed. Proceedings 39:1164; Abstract 4721 (1980, poster).

2. Swain, S.L., J. Yamamoto, R. Schwab, and R.W. Dutton. Two subsets of human T cells defined by function and ability of anti-Leu reagents to block activity, respond strongly to the allele-specific determinants of the class 1 and class 2 murine MHC antigens. Fed. Proceedings 41 (1982, oral presentation).

Janet K. Yamamoto

 3. Yamamoto, J.K., R.A. Good, H.M. Johnson, R. Engelman, R. Tyler, K. Machida, X. Tran, and N.K. Day. Augmentation of serum interferon titre prior to remission of leukemia in cats treated with ex vivo immuno-adsorption. Fed. Proceedings 42 (1983, poster).

4. Yamamoto, J.K., E.W. Ho, and N.C. Pedersen. Simultaneous production of interferon and feline leukemia virus by a continuous feline T-lymphoblastoid cell line. Fourth Intl. FeLV Meeting, Virgin Island (1983, oral presentation).

5. Yamamoto, J.K., D.E. Birch, J. Higgins, E.W. Ho, and N.C. Pedersen. Suppression of lymphocyte mitogenic response by feline leukemia virus glycoprotein gp70. Fourth Intl. FeLV Meeting, Virgin Island (1983, oral presentation).

6. Yamamoto, J.K., E.W. Ho, and N.C. Pedersen. Feline T-lymphotropic lentivirus: close resemblance to human AIDS virus. Fed. Proceedings 46 (1987, poster).

7. Yamamoto, J.K., E.W. Ho, G.H. Theilen, and N.C. Pedersen. Isolation of a feline T- lymphotropic lentivirus resembling human immunodeficiency virus (HIV). Am. Assoc. Cancer Res., Atlanta, GA (1987, oral presentation).

8. Pedersen, N.C., J.K. Yamamoto, E.E. Sparger, E.W. Ho, and R.J. Munn. Isolation of a feline T-lymphotropic lentivirus from cats with an immunodeficiency syndrome. III Intl. Confer. AIDS, San Francisco, CA (1987, oral presentation).

9. Georgiades, J.A., M. Kruzel, J. Yamamoto, D. Weigent, H. Ridgeway, J. Cummins, and D. Hutcheson. Usefulness of interferon in therapy of AIDS. In: Proceedings of First International Conference of AVIS on AIDS. S. Maggi, ed. Solei Libraria Editrice Internazionale, Italy (1988, oral presentation).

10. Yamamoto, J.K. Feline T-lymphotropic lentivirus as small animal model for AIDS. World Health Organization Conference on Animal Models of AIDS, Geneva, Switzerland (1988, invited speaker).

11. Yamamoto, J.K. Feline T-lymphotropic lentivirus as an animal AIDS model. Rhone Merieux Workshop on Animal AIDS Models, Lyon, France (1988, invited speaker).

12. Bazer, F. W., H.M. Johnson, and J.K. Yamamoto. Effect of ovine trophoblast protein-1 (oTP- 1) on replication of feline (FIV) and human (HIV) immunodeficiency viruses. Society for the Study of Reproduction, Biol Reprod 40(Suppl 1):63 (1989, poster).

13. Yamamoto, J.K. and T. Okuda. FIV-AIDS model for testing novel vaccine approaches for human AIDS. V Intl. Confer. AIDS, Montreal, Canada (1989, poster).

14. Yamamoto, J.K., H. Strandstrom, and G.H. Theilen. Infection of primary canine lymphoid cells with HIV-1. Am. Assoc. Cancer Res. (1990, poster).

Janet K. Yamamoto

 15. Yamamoto, J.K., T. Okuda, and A. Yanai. Effect of feline interferon-alpha in the therapy of FHV infection of cats. Society for Japanese Veterinary Medicine, Clinical Sciences Division, Tokyo, Japan (1990, oral presentation).

16. Yamamoto, J.K., T. Okuda, and A. Yanai. Anti feline herpesvirus and calicivirus effects of feline interferon. International Society of Interferon Research, St. Petersburg, FL (1990, poster).

17. Yamamoto, J.K., T. Okuda, and A. Yanai. Suppression of FCV viremia and clinical symptoms with recombinant feline interferon (FeIFN). Society for Japanese Veterinary Medicine, Basic Research (1990, oral presentation).

18. Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Louie, H. Zochlinski, M.B. Pembroke, E., and M.B. Gardner. Experimental vaccine protection against FIV. International Feline Immunology and Immunodeficiency Workshop (1991, invited speaker/ Section Moderator).

19. Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Louie, H. Zochlinski, E. Pembroke, V. Acevedo, K. Berger, and M.B. Gardner. Efficacy of experimental FIV vaccines. First Intl. Conference of Feline Retrovirus Researchers (1991, section moderator).

20. Yamamoto, J.K. The use of FIV-FAIDS as an animal model for AIDS therapy. Clinical Immunology Society Conference (1991, invited speaker).

21. Yamamoto, J.K. and M.B. Gardner. FIV vaccine protection vs. passive antibody protection. Septieme Colloque Des Cent Gardes. Pasteur Institute, France. (1992, invited speaker).

22. Yamamoto, J.K., T. Hohdatsu, R. Pu, H. Louie, and M.B. Gardner. Efficacy of experimental FIV vaccines. IX Intl. Confer. AIDS, 1:39, Berlin, Germany (June 6-11, 1993, oral presentation by M. Gardner).

23. Smee, D.F., J. K. Yamamoto, D.R. Warden, J.C. Diaz, and A. Glanville. SolueinTM treatment of HIV infected patients. IX Intl. Confer. AIDS, 1:492, Berlin, Germany (June 6-11, 1993, poster).

24. Yamamoto, J.K. and R. Pu. Feline immunodeficiency virus - a model for AIDS vaccine. Fed. Proceedings, p. 242A Denver, CO (May 21-25, 1993, poster).

25. Yamamoto, J.K. and M.B. Gardner. FIV vaccine update. 1993 Annual Meeting by NIH, NCI, Laboratory of Tumor Cell Biology, Hyatt Regency Bethesda, Bethesda, MD (Aug. 21-28, 1993, invited speaker).

26. Yamamoto, J.K. Vaccine program with feline AIDS virus. Intl. Confer. on Engineered Vaccines for Cancer & AIDS, Fairmont Hotel, San Francisco, CA (Sept. 30-Oct. 2, 1993, invited symposium speaker).

Janet K. Yamamoto

 27. Pu, R. and J. K. Yamamoto. Humoral immunity in FIV vaccine protection. Intl. Symp. Feline Retrovirus Research. Abst. p.48, Research Triangle Park, NC (Oct. 6-9, 1993, section moderator & oral presentation).

28. Torres, B.A., A. Varela, S. Okada, R. Pu, H.M. Johnson, J.K. Yamamoto, Characterization of virus neutralizing antibodies from FIV-vaccinated cats. Keystone Symposium on Prevention and Treatment of AIDS. J. Cellular Biochemistry, 18B:114, Hilton Head Island, SC (Jan. 23- 30, 1994, oral presentation).

29. Yamamoto, J.K.. FIV vaccines. Keystone Symposium on Prevention and Treatment of AIDS. Hilton Head Island, SC (Jan. 23-30, 1994, invited symposium speaker).

30. Okada, S., R. Pu, W.V. Stoffs, and J.K. Yamamoto. Coinfection of cats with FIV subtypes A and B: Short-term evaluation. The Sixth Workshop on the Pathogenesis of Animal Retroviruses, Fox Chase Cancer Center, Philadelphia (invited, Nov. 17-19, 1994, poster).

31. Yamamoto, J.K., FIV vaccine studies in cats. NIH, NIAID, Workshop on Live Attenuated HIV Vaccines. Rockville, MD (Feb. 10, 1995, invited speaker).

32. Yamamoto, J.K., Mitogenic effects of HIV-Nef and FIV-ORF4 on feline cells. 2nd National Conference on Human Retroviruses and Related Infections, Sponsored by The American Society for Microbiology, NIH and CDC. Washington, DC (Jan. 29 - Feb.2, 1995, invited symposium speaker).

33. Yamamoto, J.K., R. Pu, J.A. Anderson, S.C. Chari, N. Gengozian, H.M. Johnson, A. B. Peck, and J.M. Soos. Immune status of animal vaccinated against lentivirus: Feline immunodeficiency virus model for vaccine development. Experimental Biology '95, FASEB J. p. A1050, Atlanta, GA (April 9-13, 1995, poster).

34. Pu, R., S. Okada, E.R. Little, B. Xu, W.V. Stoffs, and J.K. Yamamoto. Protection of newborn kittens against FIV infection with passive maternal antibodies. Experimental Biology '95, FASEB J. p. A1050, Atlanta, GA (April 9-13, 1995, poster).

35. Okada, S., R. Pu, W.V. Stoffs, and J.K. Yamamoto. Superinfection of cats with FIV subtypes A and B. Experimental Biology '95, FASEB J. p. A1050, Atlanta, GA (April 9-13, 1995, poster).

36. Yamamoto, J.K., Mechanisms of FIV vaccine protection. XVIII Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Kyoto, Japan (Oct. 29-Nov. 3, 1995, invited symposium speaker).

37. Pu, R., S. Okada, P. Glass, M. Tellier, and J.K. Yamamoto. MHC-restricted protection against FIV infection with adoptive transfer of immunocytes from vaccinated cats. Third Intl. Symp. Feline Retrovirus Research. Abst, Fort Collins, CO (March 6-10, 1996, oral presentation by R. Pu).

Janet K. Yamamoto

 38. Mison, M., J. Elyar, S. Okada, M. Tellier, R. Pu and J.K. Yamamoto. Multi-subtype FIV vaccine confers protection against heterologous subtypes. Third Intl. Symp. Feline Retrovirus Research. Fort Collins, CO (March 6-10, 1996, oral presentation by M. Mison).

39. Okada, S., R. Pu, M. Tellier, and J.K. Yamamoto. Genetic variation of FIV isolates that escape vaccine protection. Third Intl. Symp. Feline Retrovirus Research. Fort Collins, CO (March 6- 10, 1996, poster).

40. Yamamoto, J.K., M. Tellier, and R. Pu. Adoptive transfer of immunocytes from vaccinated cats confers MHC-restricted protection against FIV infection. The ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA (June 2-6, 1996, poster).

41. Gengozian, N., S. Okada, and J. Yamamoto. Procurement of presumptive hematopoietic stem cells free of the feline immunodeficiency virus from bone marrow of infected animals. The ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA (June 2-6, 1996, poster).

42. Torres, B.A., T. Tanabe, J.K. Yamamoto, and H.M. Johnson. HIV encodes for its own CD4 T cell superantigen mitogen. The ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA (June 2-6, 1996, poster).

43. Yamamoto, J.K., M. Mison, J. Elyar, M. Tellier, and R. Pu. Efficacy evaluation of conventional dual-subtype FIV vaccine. IX Intl. Confer. AIDS, Vancouver, Canada (July 6-10, 1996, oral presentation by M. Tellier). M. Tellier received Young Investigator Award for this abstract in the IX International Conference on AIDS.

44. Arai, M., B.Dunn, and J.K. Yamamoto. AZT/3TC therapy in cats: its potential use in combination with FIV protease inhibitor. Second International Feline Immunology Workshop, Davis, CA (August 1-3, 1997, poster).

45. Arai, M., R. Pu, L. Fox, B.M. Homer, N. Gengozian, and J.K. Yamamoto. Bone marrow transplantation as immune reconstitution therapy for cats. Second International Feline Immunology Workshop, Davis, CA (August 1-3, 1997, oral presentation by M. Arai).

46. Yamamoto, J.K. History of FIV vaccines. Second International Feline Immunology Workshop, Davis, CA (August 1-3, 1997, Plenary lecturer for Vaccinology Section & section moderator).

47. Yamamoto, J.K. FIV vaccines: immunogenicity and efficacy evaluation. IBC Symposium, Tampa, FL. (February 1998, invited speaker).

48. M. Arai, D. Rerko, and J.K. Yamamoto. Allogeneic bone marrow tranplantation and antiretroviral drugs as combination therapy against FIV infection. Fourth International Feline Retrovirus Research Symposium, Glasgow, UK (May 28-31, 1998, oral presentation by M. Arai).

Janet K. Yamamoto

 48. T. Tanabe, M. Arai, L. Reyes, N. Gengozian, and J.K. Yamamoto. Novel FIV therapy: Autologous bone marrow transplantation of FIV-infected cats. Fourth International Feline Retrovirus Research Symposium, Glasgow, UK (May 28-31, 1998, poster).

49. J.S. Elyar, R. Pu, M. Arai, D. Pollock, and J.K. Yamamoto. Dual-subtype vaccine against in vivo-derived heterologous FIV challenge: Potential mechanism(s) of protection. Fourth International Feline Retrovirus Research Symposium, Glasgow, UK (May 28-31, 1998, oral presentation by J.S. Elyar).

50. Yamamoto, J.K.. Immunological assessment of BMT cats: the role of stem cell factors in BMT engraftment. Gordon Research Conference on Comparative Hematopoiesis, Tilton, NH (August 8-13, 1999, oral).

51. Arai, M., R. Pu, and J.K. Yamamoto. FIV model for AIDS immune reconstitution therapy. FASEB J. 13(4), (April 17-21) 1999 (poster).

52. Tanabe, T., M. Arai, B.A. Torres, and J.K. Yamamoto. Early FIV infection of bone marrow stroma: its significance to immune reconstitution therapy for AIDS. FASEB J. 13(4), 1999 (poster).

53. Pu, R., J. Coleman, M. Omori, C. Huang, M. Arai, T. Tanabe, and J.K. Yamamoto. Dual- subtype FIV vaccine protection against in vivo swarms of both homologous and heterologous subtype FIV isolates. Fifth International Feline Retrovirus Research Symposium, Nice, France (May 26-29, 2000, oral); JKY invited as consultant to Feline AIDS Vaccine for Europe (FAVEUR)-A Concerted Action of the European Commission.

54. Omori, M., R. Pu, T. Tanabe, and J.K. Yamamoto. FIV vaccine-induced CD8+ cell populations with strong antiviral activity. FASEB J. p. A1191, 2001 (poster).

55. M. Arai, T. Tanabe, R. Pu, and J.K. Yamamoto. Update on bone marrow transplantation (BMT) of FIV-infected cats as an immune reconstitution therapeutic model for AIDS. FASEB J. p. A1190, 2001 (poster).

56. Yamamoto, J.K. The Evolving FIV Vaccines: The First Fourteen Years. Invited speaker series in Japan. University of Tokyo, Veterinary School (May 9, 2002); Meiji Corporation (May 13, 2002); Tsukuba Primate Center for Medical Sciences, National Institute of Infectious Diseases, Tsukuba (May 14, 2002); Department of Pathobiology, Nihon University School of Veterinary Medicine (May 15, 2002).

57. Yamamoto, J.K. Brief Overview on Feline Bone Marrow Transplantation. University of Tokyo, Veterinary School (May 9, 2002, invited speaker)

58. Yamamoto, J.K. Multi-Subtype FIV Vaccine: Failures and Successes. SAIC Frederick, NCI sponsored Symposium on Inactivated Retroviral Virions: In Vitro and Vaccine Applications, p. 26 (Annapolis, MD, May 28-30, 2002, invited speaker).

Janet K. Yamamoto

 59. Pu, R., E. Sato, F. Sasaki, J. Coleman, M. Arai M, and J.K. Yamamoto. FIV antigens induce potent cross-reactive immunity to HIV-1. FASEB Journal, Abstract p. A298 (New Orleans, LA, April 21, 2002, poster).

60. Arai, M., J.W. Janelle, T. Tanabe, B.A. Torres BA, R. Pu, and J.K. Yamamoto. Humans immunized with FIV from pet cats. FASEB Journal, Abstract p. A298 (New Orleans, LA, April 21, 2002, poster).

61. Uhl, E.W., T.J. Jack, M. Arai, and J.K. Yamamoto. FIV/HIV-1 dual infection of human PBMC results in increased viral replication and cell death. FASEB Journal, Abstract p. A203 (New Orleans, LA, April 21, 2002, poster).

62. Yamamoto, J.K. FIV Vaccines. Tuft’s Animal Expo 2002 (Boston, MA, September 13-16, 2002, invited speaker).

63. Yamamoto, J.K. Vaccine for Prophylaxis and Therapeutics. Wild West Veterinary Conference (Reno, NV, October 9-16, 2002, invited speaker).

64. Yamamoto, J.K. Cytokines and Transplantation as a Novel Immunotherapy for Companion Animals. Wild West Veterinary Conference (Reno, NV, October 9-16, 2002, invited speaker).

65. Pu, P., E. Sato, J. Coleman, F. Sasaki, M. Arai, and J.K. Yamamoto. Dual-subtype FIV Vaccination in cats elicits evolutionarily cross-reactive immunity against HIV-1. 6th International Feline Retrovirus Research Symposium (Amelia Island, FL, December 2-5, 2002, poster).

66. Omori, M., R. Pu, and J.K. Yamamoto. Cellular and molecular analyses of protection induced by dual-subtype FIV vaccine. 6th International Feline Retrovirus Research Symposium (Amelia Island, FL, December 2-5, 2002, best poster in therapy division).

67. Phillips, K., M. Arai, T. Tanabe, and J.K. Yamamoto. The efficacy of recombinant human granulocyte-colony stimulating factor (rHuG-CSF) in FIV-infected cats. 6th International Feline Retrovirus Research Symposium (Amelia Island, FL, December 2-5, 2002, poster).

68. Yamamoto, J.K. Current immunobiology of feline immunodeficiency virus: its importance to FIV vaccine. 75Th Annual Western Veterinary Conference (Las Vega, NV, February 17-20, 2003, oral).

69. Yamamoto, J.K. Update on FIV vaccines. American Association of Feline Practitioners (San Francisco, CA, October 16-19, 2004, invited speaker).

70. Yamamoto J.K. AAFP Roundtable on Feline Infectious Diseases. American Association of Feline Practitioners (San Francisco, CA, October 19, 2004)

71. Yamamoto, J.K. Fort Dodge Roundtable on FIV Vaccine. American Association of Feline Practitioners (San Francisco, CA, October 18, 2004)

Janet K. Yamamoto



72. Coleman, J., R. Pu, E. Sato, M. Martin, M. Arai, and J.K. Yamamoto. HIV-1 p24 vaccine protects cats against FIV. 7th International Feline Retrovirus Research Symposium (Pisa, Italy, September 11-14, 2004, oral).

73. Pu, R., E. Sato, and J.K. Yamamoto. Dual-subtype FIV vaccine protection against virulent heterologous subtype B virus. 7th International Feline Retrovirus Research Symposium (Pisa, Italy, September 11-14, 2004, oral).

74. Tanabe, T., M. Arai, M. Volz, and J.K. Yamamoto. The therapeutic efficacy of recombinant feline granulocyte-colony stimulating factor (rFeG-CSF) in FIV-infected cats. 7th International Feline Retrovirus Research Symposium (Pisa, Italy, September 11-14, 2004, poster).

75. Yamamoto, J.K. FIV vaccines. Chiron/UC Davis/UCSF ARI TAG Vaccine meeting. March 1, 2005.

76. Yamamoto, J.K. Lessons from FIV vaccines: A link between FIV and HIV-1. University of Purdue. VPB 697 Research Seminar series, Feb. 23, 2006.

77. Ruiyu P, E. Sato, and J.K. Yamamoto. Feline immunodeficiency virus (FIV)-cat model for AIDS: T-cell immunity important for prophylactic vaccine protection. XVI Intl. Confer. AIDS, (Toronta, Canada, Aug. 13-18).

78. Yamamoto, J.K., R. Pu, and E. Sato. Probing the mechanisms of dual-subtype FIV vaccine protection. 8th International Feline Retrovirus Research Symposium (Washington, DC, October 9-11, 2006, oral).

79. Sato, E., R. Pu, and J.K. Yamamoto. Sequence analysis of MHC-I genes confirms MHC-I- restriction in dual-subtype FIV vaccine. 8th International Feline Retrovirus Research Symposium (Washington, DC, October 9-11, 2006, oral).

80. Yamamoto, J.K., R. Pu, J.K. Coleman, and E. Sato. Adoptive-transfer studies with semi- inbred cats demonstrate lentivirus-specific CD4+perforin+ CTL and CD8+granzyme- B+/interferon-γ+ CTL important for a broadly-effective AIDS vaccine. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention (Sydney, Australia, July 21-25, 2007, late breaker oral).

81. Yamamoto, J.K., E. Sato, and R. Pu. Update on the mechanisms of dual-subtype FIV vaccine protection. 9th International Feline Retrovirus Research Symposium (Vienna, Austria, August 24-28, 2008, oral)

82. Yamamoto, J.K., E. Sato, J.K. Coleman, and R. Pu. MHC-I and MHC-II restricted T cells important for a broadly-effective AIDS vaccine. Vaccine Development 2008 (Pittsburgh, PA, September 28-30, 2008, oral).

Janet K. Yamamoto

 83. Yamamoto, J.K. Viral-specific T-cell immunity essential for AIDS vaccine. 2008 Vaccinology Seminar Series, BIOS 5970, Western Michigan University, October 20, 2008.

84. Yamamoto, J, J. Coleman, R. Pu, and J. Levy. FIV-cat model for selecting viral proteins for HIV-1 and FIV vaccines. 16th Conference on Retroviruses and Opportunistic Infections (Montreal, Canada, February 8-11, 2009).

85. Yamamoto, J.K., E. Sato, J.K. Coleman, and R. Pu. Lenvirus-specific CD4+ granzyme- A+/perforin+ CTL and CD8+ granzyme-B+/interferon-γ+ CTL important for a broadly-effective AIDS vaccine. Prevention of HIV/AIDS (X3) (Keystone, CO, March 22-27, 2009).

86. Coleman, J.K., R. Pu, J.K. Yamamoto. Efficacy of HIV-1 and FIV subunit vaccines against FIV. Immunology 2009, The 96th Annual Meeting of The American Association of Immunologist (Seattle, WA, May 8-12, 2009).

87. Yamamoto, J.K. Evolving perspectives on FIV vaccines. Feline practitioner’s meeting for Canada (Toronto, Canada, July 1, 2009).

88. Yamamoto, J.K. Feline immunodeficiency virus (FIV)-cat model: T-cell based HIV/FIV vaccines. TRIAD Toolkit Training meeting. Invited Speaker (University of Rhode Island, Providence, RI, May 10-11, 2010)

89. Sanou, M.P., J.K. Coleman, R. Pu, and J.K. Yamamoto. Cross-reactive FIV epitopes in the development of an HIV-1 vaccine for humans. 10th International Feline Retrovirus Research Symposium (Charleston, SC, May 23-26, 2010, oral)

90. Sanou, M.P., J.K. Coleman, J.A. Levy, and J.K. Yamamoto. Identification of cross-reactive FIV epitopes as potential immunogens in an HIV-1 vaccine. AIDS Vaccine 2010 (September 28 – October 1, 2010, poster).

91. Yamamoto, J.K. FIV-cat model for HIV-1 vaccine. 8th Annual Vaccines: All Things Considered. GTCbio sponsored. Invited Speaker (Washington DC, November 8-9, 2010).

92. Sanou, M.P., J.K. Coleman, R. Pu, J.A. Levy, and, J.K. Yamamoto. Selection of conserved HIV-1 vaccine epitopes based on cross-reactivity to feline immunodeficiency virus (FIV). Immunology 2011, 98th Annual Meeting of The American Association of Immunologists (San Francisco, CA, May 13-17, 2011).

93. Yamamoto, J.K., J.K. Coleman, R. Pu, and J.R. Abbott. Modulation and broadening of T-cell epitope responses after 4 years of vaccination with dual-subtype feline immunodeficiency virus (FIV) vaccine. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (Rome, Italy, July 17-20, 2011).

94. Kondo, H., Sakagawa, Y., Coleman, J.K., Offner, M.J., Coisman, J.G., Yamamoto, J.K., and Abbott, J.R. Prolonged and enhanced efficacy of pegylated feline granulocyte colony- stimulating factor in FIV-infected and uninfected laboratory cats, and in cats with HuG-CSF

Janet K. Yamamoto

 induced neutropenia. The American College of Veterinary Pathologists 62nd Annual Meeting / The American Society for Veterinary Clinical Pathology 46th Annual Meeting (ACVP), December 3-7, 2011, Nashville, TN (poster). 95. Roff, S, Sanou, M., Aranyos, A., Pu R., Rathore, M., Levy, J., Yamamoto, J.K. T-cell based lentiviral vaccines. 17th Annual International Meeting of the Institute of Human Virology, September 27-30, 2015, Baltimore, MD (poster).

96. Roff, SR., Aranyos, A.M., Pu R., Owen, J.L., Zoll, W.M., Yamamoto, J.K. Thyroid hypertrophy in cats infected with highly pathogenic feline immunodeficiency virus. 2015 Combined Annual Meeting of The American College of Veterinary Pathologists (ACVP) / The American Society for Veterinary Clinical Pathology (ASVCP / Society of Toxicologic Pathology (STP), October 17-21, 2015 Minneapolis MN (poster).

97. Yamamoto, J.K. A need for T-cell based vaccines against AIDS lentiviruses. 9th Global Summit and Expo on Vaccines & Vaccination. Invited Speaker (San Francisco, CA, November 30-December 2, 2015) (oral).

98. Yamamoto, J.K., Designing an effective T-cell based HIV-1 vaccine. 9th Global Summit and Expo on Vaccines & Vaccination. Invited Speaker for workshop (San Francisco, CA, November 30-December 2, 2015)(oral).

REVIEWS OF NOMINEE'S WORKS:  The President (David Pierpont Gardner) of the University of California. AIDS research: Davis campus is co-creator of AIDS vaccine for cats. A Report (The President's periodic report to The Regents), p. 29, 1990.

 Hale, P. The FIV connection: Why cats may be the purr-fect model for HIV infection. Searchlight- AIDS RESEARCH Alliance, Summer, 1996, 21-23.

 Hale, P. Feline retroviruses. Searchlight- AIDS RESEARCH Alliance, Summer, 1996, 24-25.

MEDIA RELEASES: Media releases that cites my work.

Interviews (Radio/TV):  Public Broadcasting Station from Florida on the discovery of FIV and its significance, TV program, 1988.  Public Broadcasting Station from Washington D.C. for dual-subtype FIV vaccine and its significance, Radio, at 1996.

Newspapers and Congressional Record:

 Janet K. Yamamoto As co-discoverer of feline immunodeficiency virus (FIV) and the sole discoverer of the FIV vaccine recently released for commercial use, I have been interviewed by numerous reporters including the Associated Press and United Press International. There are over 38 newspaper articles reporting our work. Only those newspaper articles with the page numbers have been included.

1. Blum, Deborah. UC Davis study uncovers AIDS-like virus in cats. The Sacramento Bee, Metro section pp.B1-B2. February 13, 1987.

2. Baum, Rudy. Felines AIDS virus identified. Chemical & Engineering News, p.33. March 2, 1987.

3. The Associated Press. Virus in domestic cats may lead to AIDS cure. Virus in domestic cats may lead to AIDS cure. Gloucester Times, Gloucester, NJ, pp. A-1 and A-11. February 13, 1987.

4. The Associated Press. AIDS-like virus could threaten cats but help in research. Canton Repository, Canton, Ohio, pp. 1 and 3. February 13, 1987.

5. Butterfield, Fox. AIDS-like virus found in many domestic cats. The New York Times - National, p. 12. Saturday, July 13, 1991.

6. Palmer, Megan. Professor organizing HIV research center. Alligator, p. 4. Wednesday, December 1, 1993.

7. Wolter, Renae. Researchers meet at UF AIDS forum. Alligator, p.5. Tuesday, February 15, 1994.

8. Magrin, Jud. UF scholars hope to bring AIDS researchers together. The Gainesville Sun, p. 6B. February 15, 1994.

9. Scribe Newswire, March 22, 2002 Friday, 884 words, University of Florida Researcher Develops AIDS Vaccine for Cats.

10. The Associated Press State & Local Wire, March 22, 2002, Friday, BC cycle, State and Regional, 372 words, Florida researchers develops feline AIDS vaccine; GAINESVILLE, Fla.

11. The Associated Press State & Local Wire, March 22, 2002, Friday, BC cycle, State and Regional, 372 words, Florida researchers develops feline AIDS vaccine, GAINESVILLE, Fla.

12. XINHUA GENERAL NEWS SERVICE, March 22, 2002, Friday, WORLD NEWS; SCIENCE, CULTURAL, EDUCATION, HEALTH, 251 words, U.S. Approves First AIDS Vaccine for Cats, WASHINGTON.

13. The Houston Chronicle, March 30, 2002, Saturday, 3 STAR EDITION, A;, Pg. 1, 681 words, AIDS vaccine offers hope for cats, LEIGH HOPPER, Houston Chronicle Medical Writer, Acquired Immune Deficiency Syndrome Medicines.

Janet K. Yamamoto

 14. The Associated Press State & Local Wire, March 30, 2002, Saturday, BC cycle, State and Regional, 489 words, Vaccine for cat AIDS soon to be available, HOUSTON.

15. U.S. News & World Report, April 8, 2002, Science & Technology; Futures; Vol. 132, No. 11; pg. 56, 135 words, Cool for cats, Nell Boyce.

16. AIDS Weekly, April 22, 2002, EXPANDED REPORTING; Pg. 7, 885 words, AIDS THERAPY: UF researcher develops AIDS vaccine for cats.

17. Vaccine Weekly, April 24, 2002, EXPANDED REPORTING; Pg. 8, 885 words, AIDS THERAPY: UF researcher develops AIDS vaccine for cats.

18. The Herald (Glasgow), July 11, 2002, Pg. 12, 1649 words, Feline plague on the prowl;A cat on a lead? It's just one of the drastic steps anxious cat owners are taking to protect their pet against the cat form of HIV. Rebecca McQuillan reports, Rebecca Mcquillan.

19. FDA Consumer Magazine, Research Notebook - July-August FDA Consumer, 323 words, First vaccine for cat AIDS approved for veterinary use. FDA Consumer.

20. Deseret News (Salt Lake City), July 19, 2002, Friday, LOCAL;, Pg. B01, 618 words, New vaccine puts bite on feline form of AIDS, By Callie Buys Deseret News staff writer.

21. The Sun Herald, August 8, 2002, Thursday, LIFESTYLE, K2195, 784 words, Vaccine now exists for FIV, By Dr. Tracy Acosta.

22. U.S. Newswire, August 12, 2002 Monday, National Desk, 533 words, First Feline AIDS Vaccine Available. 23. PR Newswire, August 12, 2002, Monday, FINANCIAL NEWS, 870 words, First Feline Aids Vaccine Available, OVERLAND PARK, Kan., Aug. 12.

24. The Houston Chronicle, August 20, 2002, Tuesday, 2 STAR EDITION, HOUSTON;Pg. 3, 459 words, New FIV vaccine offers 'Kitty AIDS' protection, STEVE DALE.

25. The Augusta Chronicle (Georgia), August 22, 2002 Thursday, ALL EDITIONS, TV PAGE, Pg. D04, 448 words, CAT VACCINE MAY HELP IN SEARCH FOR AIDS CURE.

26. The Record (Bergen County, NJ), September 5, 2002 Thursday All Editions, HOME; PET Q&A; Pg. F05, 436 words, Vets wary of FIV vaccine, CATHY KRZECKOWSKI.

27. The Sun Herald, September 12, 2002, Thursday, LIFESTYLE, K7213, 417 words, 'Feline AIDS' vaccine now available, By Dr. Chris Duke.

28. The Record (Bergen County, NJ), September 26, 2002 Thursday All Editions, HOME; PET Q&A; Pg. F05, 463 words, Feline virus vaccine not for all cats, CATHY KRZECKOWSKI.

Janet K. Yamamoto

 29. United Press International, October 12, 2002, AEGIS-UPI, Cats could help find HIV vaccine. Steve Mitchel (UPI Medical Correspondent) (http://www.aegis.com/news/upi/2002/UP021008.html).

30. The Dallas Morning News, November 7, 2002, Thursday, LIFESTYLE, K1152, 454 words, Indoor cats unlikely to contract FIV, By Dr. Shawn P. Messonnier.

31. Sunday Times (South Africa), August 24, 2003, Health; Pg. 5, 462 words, Vaccine available for 'cat Aids', Claire Keeton.

32. Fox New. October 4, 2013 322 words. Cats may be the key to developing a successful HIV vaccine for humans. By FoxNews.com.

33. The Gainesville Sun, October 5, 2013, 512 words, UF expert finds cats may offer clues for an HIV vaccine. By Kristine Craine.

34. Congressional Record– Extension of Remarks February 20, 2015 by Dennis A. Ross (House of Representatives) honoring recipients of 2014 National Academy of Inventors.